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ABSTRACT 
INTER-PROFESSIONAL COLLABORATION BETWEEN 
GENERAL PRACTITIONERS AND COMMUNITY PHARMACISTS: 
GENERAL PRACTITIONERS’ PERSPECTIVES 
E.O EGIEYEH 
M. Pharm thesis, School of Pharmacy, University of the Western Cape 
 
The global movement towards enhancing inter-professional collaboration in patient 
care is in light of the increasing potency of drugs and complexity of drug regimens, 
particularly in the chronically ill where poly-pharmacy is rife, collaborative patient 
management by general practitioners and community pharmacists, in particular, has 
the potential to enhance patient therapeutic outcomes in primary healthcare.   
Literature from other parts of the world has enumerated the advantages of 
collaboration. South Africa with its unusual quadruple burden of disease and human 
resource deficient public healthcare system would benefit from collaboration 
between general practitioners and community pharmacists through expanded roles 
for community pharmacists to enable them to make more meaningful contributions 
to primary healthcare regimens. Particularly with the introduction of the National 
Health Insurance (NHI) programme.  
This dissertation aims to assess from general practitioners‟ perspectives: the current 
level and stage of collaboration (using the collaborative working relationship (CWR) 
model proposed by McDonough and Doucette, 2001) between general practitioners 
and community pharmacists in patient care, if general practitioners‟ perceptions of 
the professional roles of community pharmacists in patients‟ care can influence 
desired collaboration (prospects of enhanced future collaboration) and how do 
general practitioners envision enhanced future collaboration between them and 
community pharmacists in patient care, possible barriers to the envisioned 
collaboration between the two practitioners, and how general practitioners‟ 
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demographic characteristics influence inter-professional collaboration with 
community pharmacists. 
Sixty randomly selected consenting general practitioners in private practice 
participated in a cross-sectional, face- to-face questionnaire study. The questionnaire 
contained a range of statements with Likert scale response options. Data was 
initially entered into Epi Info (version 3.5.1., 2008) and then exported to IBM SPSS 
Statistical software for analysis (version19, 2010). Medians were used to summarize 
descriptive data and Spearman‟s correlation coefficient, Mann-Whitney U Test and 
Kruskal-Wallis Test was used for bivariate analysis. Ethical approval was granted by 
the Senate Research and International Relations Committee, University of the 
Western Cape (Ethical Clearance Number: 10/4/29). 
The results indicated low-levels of current collaboration at stage 0 of the CWR 
model between general practitioners and community pharmacists. A statistically 
significant correlation was observed between general practitioners‟ perceptions of 
the professional roles of community pharmacists and desired collaboration 
(prospects of enhanced future collaboration), [p=0.0005]. Good prospects of 
enhanced future collaboration between general practitioners and community 
pharmacists were observed. General practitioners identified barriers to collaboration 
to include: the lack of remuneration for collaboration, absence of a government 
mandate or policy supporting collaboration, inability of general practitioners to 
share patients‟ information with community pharmacists and questionable 
professional ethics exhibited by community pharmacists particularly over financial 
gains. Most general practitioners agreed that joint continuing professional education 
organized by pharmaceutical companies or other groups will increase interaction and 
enhance collaboration. 
Enhanced Inter-professional collaboration between general practitioners and 
community pharmacists‟ can be possible in the future but hindrances need to be 
eliminated for this to be achieved. Future research can be aimed at exploring the 
perspectives‟ of community pharmacists to inter-professional collaboration in South 
Africa and interventions that will enhance collaboration. 
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CHAPTER ONE 
INTRODUCTION 
Globally, there is a growing trend towards enhancing collaborative practices 
between general practitioners and community pharmacists who are involved in 
patient management with the aim of improving therapeutic outcomes (Woodend, 
2003; Bajcar et al., 2005; Department of Health, England, 2006). Enhanced inter-
professional collaboration in drug management is needed in light of the ever 
increasing potency of drugs and complexity of drug regimens, particularly in the 
chronically ill where poly-pharmacy is most often the standard rather than an 
exception (Chobanian  et al., 2003; Canadian Diabetes Association, 2003; Bajcar et 
al., 2005). Moreover, medications can have side effects, can produce adverse 
reactions, and may interact with other medications, food, or over-the-counter 
medicines leading to adverse events in patients (Lee et al., 2009). 
Studies in England and South Africa have shown that the pharmacy is used as a 
„first port of call‟ for minor ailments by most people (Gilbert, 1998; Hassell et al., 
2000; Hammond et al., 2004). A ministerial statement from the Department of 
Health (DoH) in England states that most people (99%), irrespective of their 
location can access a pharmacy within 20 minutes by car, walking or public 
transport (DoH, England, 2006). Hence, community pharmacists are easily 
accessible sources of primary care (International Pharmaceutical Federation, 2007). 
They can also act as referral points for general practitioners (Hassell et al., 2000). 
A systematic review of studies addressing drug-related problems that resulted from 
visits to the emergency department showed that medications were responsible for 
approximately 28% of emergency visits to hospitals and such medication related 
problems are believed to be preventable in more than 50% of the cases (MacDonell 
& Jacobs, 2002; Howard et al., 2003).  Furthermore, a prospective study of fourteen 
United Kingdom (UK) community pharmacies also showed that the prescriber had 
to be informed to make clinical pharmacy interventions on 80 (0.89% of items 
dispensed) occasions out of 9000 items dispensed, and an independent clinical panel 
assessed that 15 (0.35% of items dispensed) could have resulted in hospital 
admission if unidentified and unchanged (Hawksworth & Chrystyne, 1994).  
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Another benefit that is obtainable from the collaboration between general 
practitioners and community pharmacists was highlighted in an asthma-management 
study conducted at the University of Tasmania, Australia.  This study confirmed that 
patients‟ health outcomes can be improved if pharmacists are more completely 
involved in their care. Participants who had been actively involved in reviewing 
patients dispensing histories were used as study participants. They provided 
educational resources such as the Asthma Foundations' asthma fact brochure to 
educate patients who may not have thought their symptoms of asthma required 
review. The information provided by the pharmacists to their patients suggested that 
the patients need to visit their general practitioners to discuss their current asthma 
management. The interventions resulted in fewer patients being reliant solely on 
reliever medication and encouraged more appropriate use of preventers (Bereznicki 
et al., 2008).  
Also, a study conducted in Hong Kong showed that a pharmacist–physician co-
managed programme for hyperlipidaemic patients effectively assisted patients in 
reaching target lipid levels.  In this study, pharmacists interviewed patients in the 
intervention group for 15-30 minutes after their regular clinic visit to provide 
consultation on the drug regimen and lifestyle modifications. A telephone follow-up 
every 4 weeks and a follow-up interview on the date of the physician visit were 
scheduled while patients in the control group received routine conventional care 
(Lee et al., 2009). 
A joint statement by the International Pharmaceutical Federation (IFP) and World 
Medical Association at the 1998 Pharmacy World Congress, The Hague, 
Netherlands, reiterated the extent of dependency between the roles of the physicians 
and pharmacists in achieving optimal medicinal therapy. It also stated that 
practitioners need to recognize and respect each other‟s professional competence, 
communicate effectively and be trustworthy for this to be achieved (Pharmacy 
World Congress, 1998). 
Moreover, given the extent of medicine management issues and the possibility of 
more efficient use of resources within the healthcare system, it is important that 
general practitioners and community pharmacists cooperate to combine their skills 
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in order to address and avert drug related problems, improve therapeutic outcome 
and promote judicious use of resources (DoH, England, 2006).  However, conflict 
between general practitioners and community pharmacists over determination of 
professional task boundaries and domain greatly undermines the benefits obtainable 
from such collaboration (Gilbert, 1998).                                                
There is a dearth of published studies addressing this important issue in South Africa 
and little is known about the perceptions of pharmacists or general practitioners 
towards collaboration in practice. Several factors have been suggested which might 
have inhibited collaboration within the healthcare team (Dobson et al., 2006; 
Bradley et al. 2008). This includes the difference in status, prestige and power 
accorded to different members of the healthcare team (Harding & Taylor, 1990). 
Additionally a lack of communication and misunderstanding of roles by general 
practitioners and other members of the primary healthcare team have been reported 
to undermine the potential of the primary healthcare team (Pringle et al., 2000; 
Sicotte et al, 2002). Some studies conducted in Canada, Europe and the United 
States of America (USA) investigated the attitudes of general practitioners to inter-
professional collaboration with community pharmacists (Howard et al., 2003; 
Bryant et al., 2009; Pojskic et al., 2009) but none have thus far been done in South 
Africa, which has its own peculiar burden of disease, political, and historical 
backgrounds. 
The primary objective of this thesis is to determine the extent of inter-professional 
collaboration between general practitioners and community pharmacists. To achieve 
this, the perspective of the general practitioners on the current level and stage of 
collaboration with community pharmacists in patient care on the one hand, and the 
perceptions of the professional roles of community pharmacists and how they can 
influence the desired collaboration between them, were assessed. Furthermore, how 
general practitioners envision enhanced future collaboration between them and 
community pharmacists in patient care as well as possible barriers to the envisioned 
collaboration between general practitioners and community pharmacists in patient 
care in South Africa were also assessed. 
 
 
 
 
4 
 
The second chapter summarizes a review of relevant literature that corroborates the 
positive influence of enhanced collaborative practices between general practitioners 
and community pharmacists on patients‟ health outcomes. These advantages are 
extracted from local and international government policies and legislative 
documents, statements from local and international pharmacy and medical 
professional bodies, published research study findings and reviews. The added 
advantage of enlisting and judiciously utilizing community pharmacists in the poorly 
resourced primary healthcare system in South Africa as is done in some other parts 
of the world was also emphasized. 
In the third chapter, the research aim and objectives are outlined. Chapter four 
presents the research design and the methods used in executing the study, statistical 
and ethical issues. Results obtained in the thesis are presented in chapter five. Data 
was descriptively and inferentially analyzed, and a summary of the main findings 
concludes chapter five. The main findings observed in the thesis are discussed in 
chapter six with the main hypothesis and the research questions being central to the 
discussion. Chapter seven concludes the thesis and it contains conclusions and 
recommendations generated in the course of the study.  
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 INTRODUCTION 
This chapter presents literature reviewed from published research study findings, 
reviews, government policies, legislative documents, statements from 
pharmaceutical and medical professional bodies, and the World Health Organization 
(WHO). The review explores collaboration as a global phenomenon in different 
organizations then focuses on the healthcare system. Conclusions are reached here 
that for safe delivery of effective healthcare, collaboration is essential. Historical 
interdependence of pharmacy and medicine is established with the subsequent 
separation and advancement, of the roles of pharmacists. Primary healthcare is 
reviewed; evidence and advantages of collaboration in hospitals and clinics are 
outlined. Global trends in inter-professional collaboration between general 
practitioners and community pharmacists, the need for it and the benefits thereof are 
reviewed. Lastly, the benefits of collaborative practices between general 
practitioners and community pharmacists to South Africa with its peculiar quadruple 
burden of disease are also highlighted. 
2.2 COLLABORATION: A GLOBAL PHENOMENON 
Organizations, consultants, practitioners, and academics worldwide are increasingly 
commending the importance of collaboration and the significant benefits it 
promises, inter alia, improved customer service, better inventory management, more 
efficient use of resources, and increased information sharing (Daugherty et al., 
2006). With these in view, many organizations are now reliant on teamwork as it has 
been confirmed that the success or failure of an organization depends on the ability 
of its people to work together effectively in teams (Smith-Blancett, 1994; 
Margerison & McCann, 1995; Mohrman, Cohen & Mohrman, 1995; Edelman et al., 
2004). Examples of collaborative practices can be seen in the automobile industry 
between General Motors (GM) and Consolidated Freightways (CNF); suppliers and 
retailers like Wal-Mart and Procter & Gamble (P & G) are using the collaborative 
planning forecasting and replenishment (CPFR) profiles to meet the demands of 
consumers (Attaran, 2004). 
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2.3 COLLABORATION IN THE HEALTHCARE SYSTEM 
Effective and safe delivery of healthcare is a major concern of the governments of 
most countries in the world. It is typical for countries to allocate a portion of health 
budgets towards ensuring the provision and delivery of this standard of healthcare. 
The delivery of healthcare services is committed to qualified health professionals 
such as doctors, nurses, pharmacists, physiotherapists, and several others. Each of 
these varied health practitioners is independently professional in their various areas 
of expertise (Knox & Simpson, 2004).  For effective and safe delivery of healthcare, 
health professionals need to collaborate, communicate, and engage in teamwork 
(Kohn et al., 2000).  
Team work can be viewed by employers and staff as an asset, but it is a prerequisite 
for patients.  Cohen and Bailey, (1997) defined a team as a group of individuals who 
see themselves as a unit in one or more social systems and are mutually-dependent 
in executing their tasks, share the liability for the outcomes, and are able to cordially 
relate across organizational borders.  In a research report authored by Oandasan et 
al. (2006), it is stated that different kinds of teams are available in healthcare 
although not all health professionals operate as teams. In this regard, teamwork can 
then be defined as the connection between two or more health professional relying 
on each other to provide care for the patients. Teamwork requires that members of 
the team are interdependent, work collaboratively and benefit from doing so to 
provide patient centred care. Team members are required to communicate or share 
information and share decision making where necessary. The author‟s opinion is that 
teamwork can, therefore, be seen as a product of collaboration. Collaboration is also 
defined as the process of developing interactions and relationships between health 
professionals despite being part of a team or not (Oandasan et al. 2006). Therefore, 
collaboration can exist amongst health practitioners who are not a team, particularly 
amongst independent private practitioners in community settings. 
 
Inter-professional collaboration within healthcare teams has been described as an 
efficient, effective and satisfying way to offer healthcare services (Alpert et al., 
1992; Baker et al., 2006). It is a process through which independent professionals 
voluntarily and collectively work together to meet patients‟ healthcare needs after 
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necessary negotiations and the removal of all forms of competitiveness between 
different professionals and health institutions has been achieved (San Martin-
Rodriguez et al., 2005). A recent national report on the direction of primary care 
delivery in Canada has advised that prescription drugs could be more effective if 
individual patients are monitored continuously by teams and networks of healthcare 
providers (Bajcar et al., 2005).  
 
Different kinds of collaboration occur depending on the type of care required by the 
patient. Interdependent and inter-professional practices are established when 
healthcare requires referral to another professional. Way et al. (2000) defined 
collaborative practice as the process of using inter-professional communication and 
decision making that promotes collaboration based on shared knowledge and a range 
of professional skills to affect patient care. This idea of collaborative practice is 
shared by McDonough and Doucette, (2001) in their collaborative working 
relationships (CWR) model which defines the processes (stages) that relationships, 
particularly between general practitioners and community pharmacists, need to go 
through before commitment to collaborative practices are achieved between health 
professionals.   
 
2.3.1      ELEMENTS ESSENTIAL FOR COLLABORATION 
Certain essential interdependent elements have been found to contribute to the 
process of collaboration (Poulton & West, 1999). Thompson JD, in his 1967 model 
of organizational theory described collaboration as “high-level cooperativeness and 
assertiveness to solve problems where there are common interests and the stakes are 
high” (Thompson, 1967). From this description co-operation and assertiveness are 
identified as essential elements for collaboration. Communication, trust, self-
confidence, confidence in other healthcare partners, autonomy, mutual respect, and 
the feeling of shared responsibility are other elements required for effective 
collaboration (Oandasan et al., 2006). Researchers have also described certain 
specific competencies related to the essential elements described above that have 
been found to influence effective collaboration. These competencies include: 
knowledge of healthcare professional roles, ability to communicate effectively with 
other health professionals, ability to appreciate the roles of other health 
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professionals, attitudes related to mutual trust, and willingness to collaborate (San 
Martin-Rodriguez et al., 2005; D‟Amour & Oandasan, 2005; D‟Amour et al., 2005). 
Oandasan et al. (2006) stated that these competencies prove that being an effective 
collaborator can be learned. The importance of effective communication between 
healthcare professionals was emphasized in the report of an observational study of 
communication in operating rooms carried out by Lingard et al. (2004). They found 
that one-third of the exchanges between staff failed and a third of these 
communication failures potentially jeopardized patients‟ safety. San Martin-
Rodriguez et al. (2005) explained that for effective collaboration, clear structures 
that outline team objectives, roles and responsibilities of team members, 
mechanisms for exchanging information, and co-ordination mechanisms for team 
activities and staffing, all need to be put in place.  
 
Globally, collaborative practices are being explored between different members of 
the healthcare team to develop, test and evaluate new models of service delivery that 
would improve patients‟ health outcomes (Sellors et al., 2003; Bajcar et al., 2005).  
Makowsky et al. (2009) in Canada carried out a qualitative research using key 
informant interviews and reflective journaling to gather information on the working 
relationships existing between pharmacists, physicians and nurse practitioners in an 
inpatient medical setting. It was designed as a multicentre, controlled clinical trial of 
team-based pharmacist care in hospitalized medical patients. Data analysis was done 
using a phenomenological approach. The primary tool used to categorize and 
identify emerging themes was content analysis.  In the course of introducing 
pharmacists into the medical team, the researchers observed that they had moments 
of exhilaration when they developed trusting relationships and made positive 
contributions to patient care. They also had unpleasant moments when they had to 
struggle with documentation and workload. On the whole, all participants agreed 
that the integration of pharmacists into the teams improved team drug-therapy 
decision making; hence, it positively improved patient health outcomes. An 
increased awareness of the potential roles of all the team members was observed in 
this study. This would engender appreciation of the role each team member has to 
play and health professionals can benefit from working together as a team. The 
authors opined that „focused attention on how practice is structured, team process 
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and on-going support would enable successful implementation of team-based care in 
a larger context‟ (Makowsky et al., 2009).  
 
The influence of the awareness of the professional roles and skills of each member 
of the healthcare team on collaborative practice is also emphasized in a study carried 
out in the United Kingdom. Dalley and Sim, (2001) studied nurses‟ perceptions of 
physiotherapists as members of the rehabilitation team, using semi-structured 
interviews. Experienced rehabilitation nurses were recruited in two rehabilitation 
wards within a National Health Service Trust (NHST). They observed that nurses‟ 
perceptions of the roles and skills of physiotherapists were limited to mobility and 
movement and as such they presumed physiotherapy to be specific and measureable 
compared to nursing which they believed was generalized and undefined. Nurses 
also perceived that physiotherapists lacked adequate knowledge of the nursing 
profession. They considered the two professions to have distinct and different roles 
in rehabilitation. These perceptions influenced collaboration between the nurses and 
physiotherapists and created barriers to rehabilitation of patients as nurses were 
underestimating the role and knowledge of physiotherapists based on their 
perceptions. Nurses and physiotherapists would need to imbibe the competencies 
outlined earlier to be effective collaborators so that their patients can benefit from 
their professional training through collaborative practices. 
 
Collaboration between healthcare practitioners in the hospital or clinical setting with 
the typical institutionally based enclosed manner is enhanced by the proximity they 
enjoy (Harding & Taylor, 1999). Baggs and Schmitt, (1997) in their study of 
collaboration among residents and nurses identified that they had to be in close 
proximity. In private primary healthcare community settings, collaboration between 
independent health practitioners might be hindered by more factors than are 
obtainable in hospital settings. The practice of medicine and pharmacy in the 
community has existed since the separation of pharmacy from medicine in the 19
th
 
century.  
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2.4 HISTORICAL INTER-DEPENDENCE OF PHARMACY AND 
MEDICINE 
Historically, pharmacy and medicine were practiced as a single profession. The 
increase in scientific, medical and pharmaceutical knowledge made this intertwining 
impossible as the task allotted to each began to increase and diverge (Angorn & 
Thomison, 1985; Cowen, 1992; Gilbert, 1998). Later it became increasingly 
necessary and reasonable to differentiate medicine from pharmacy as two 
independent professions (Angorn & Thomison, 1985; Flannery, 2001). With the role 
differentiation, physicians made diagnoses of health conditions and prescribed 
appropriate medications while pharmacists compounded and dispensed such 
medications (Matowe et al., 2006). Since the 1990s however, the role of the 
pharmacist has evolved from being drug-based to being patient-oriented, 
incorporating roles in health promotion and medication management reviews and 
modelling the concept of pharmaceutical care, thereby earning pharmacists a role in 
primary healthcare (Anderson, 2007; Rigby, 2010). Sadly, the differentiation of the 
roles of the general practitioner and pharmacist has also led to the disintegration of 
relationships between the two professions (Turner, 1995). Moreover, recent 
literature has shown this to be a disadvantage to the patient and the healthcare 
system, particularly in community practice (Bajcar et al., 2005). 
2.5 COLLABORATION IN PRIMARY HEALTHCARE 
Primary healthcare is defined as the first level of care or the entry point to the 
healthcare system for consumers. In 1978, the World Health Organization (WHO) 
defined primary healthcare as essential healthcare that has been scientifically proven 
and is practicable using methods and techniques that are socially acceptable. This 
form of healthcare should be accessible and affordable for all the members of a 
community and requires their full participation to maintain healthy lifestyles (WHO, 
1978). Primary healthcare is intended to transform healthcare from being curative to 
being more preventive through the active participation of community members who 
recognize opportunities for change. It involves the education of community 
members on the identification, prevention and control of prevailing health 
challenges, provision of preventive and curative care for infectious, endemic and 
non-communicable diseases through the provision of immunizations and essential 
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drugs (WHO, 1978). It is holistic care close to the people at affordable cost within a 
community. By this definition, healthcare delivery is not restricted to hospitals, 
clinics and health centres but requires the input of all professional healthcare 
practitioners in the community settings. 
 Sicotte et al. (2002) observed that the objectives of primary healthcare have not 
been achieved 30 years after the WHO definition. They were of the opinion that 
inter-professional collaboration in hospitals and collaboration between all the stake 
holders is essential for these objectives to be actualized. Pringle et al. (2000) also 
agreed with this opinion. In addition to advocating for inter-professional 
collaboration amongst health professionals caring for patients in the hospitals and 
clinics which are mostly government funded, private sector primary healthcare 
providers including general practitioners and community pharmacists also need to 
collaborate for more efficient healthcare delivery. Prescriptions generated either in 
the hospital or from a family physician, if not filled on-site usually end up with the 
community pharmacist. Relationships between general practitioners and community 
pharmacists are not as formalized as those found in organized settings such as health 
centres and hospitals, but evidence abounds that collaboration between general 
practitioners and community pharmacists would result in improved patient 
therapeutic outcomes (Boudreau et al., 2002; Rigby, 2010).  In the United Kingdom, 
the Department of Health in collaboration with the National Health Service (NHS) 
and the Pharmaceutical Services Negotiating Committee (PSNC) published a 
community pharmacy contractual framework which listed the advantages of 
collaboration between general practitioners and community pharmacists to the 
patients, general practitioners and the Primary Care Trust (PCT). The advantages 
include: saving general practitioners time by undertaking repeat prescriptions, 
saving prescription costs, reducing the workload of general practitioners, wider 
availability of services, and better patient experience (PSNC, 2004). 
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2.5.1  GENERAL PRACTITIONER-PHARMACIST COLLABORATION IN                        
HOSPITALS AND CLINICS 
Studies have shown that successful integration of pharmacists into healthcare 
settings and drug therapy management has resulted in improved prescribing and 
therapeutic outcomes and more judicious use of human and material resources 
(Carter et al., 2001; Bond et al., 2002; Boudreau et al., 2002; Borenstein et al., 
2003; Doucette et al., 2005). Harding and Taylor, (1990) studied the professional 
relationships between general practitioners and pharmacists in 10 health centres with 
integral pharmacies from each of the ten regional authorities in England. A 
qualitative study design was used to characterize how general practitioners saw their 
relationship with community pharmacists, using semi-structured interview schedules 
to ensure that participants were asked the same questions. Thirteen general 
practitioners and ten pharmacists were enlisted for the study from health centres 
with pharmacies while nine general practitioners from health centres without 
pharmacies and ten managers of community pharmacies in the same vicinity were 
also interviewed for comparative studies. The interview schedules included 
questions on the nature of pharmacists‟ queries to general practitioners, the attitude 
of general practitioners to such queries and the impact of pharmacists on their 
selection of prescribed medication. Managers of the ten health centres with 
pharmacies were interviewed and their responses were used to characterize 
pharmacists‟ perceptions of their relationship with prescribers. Pharmacists were 
questioned on the opportunities they have had for informal interactions with other 
healthcare professionals and perceived relationship with other healthcare 
professional and the procedure for handling prescription queries. The results showed 
that general practitioners in health centres with integrated pharmacy units 
communicated and collaborated more with pharmacists than their colleagues who do 
not have on-site pharmacies. This relationship is believed to be enhanced by 
proximity since face to face interactions, telephone calls or third party interventions 
can be done quickly. General practitioners also saw on-site pharmacies as being a 
huge information resource, convenient for patients, and they appreciated the 
availability of emergency supplies during surgery hours. They were comfortable 
contacting pharmacists on drug queries and welcomed the same from them. Most 
general practitioners perceived their working relationship to be in terms of the 
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exchange of their respective expertise and did not attach any personal relationship to 
it. Health centre pharmacists were also observed to consult general practitioners on a 
wider range of drug queries compared to community pharmacists although they 
indicated that working relationships would be more satisfactory if general 
practitioners exploited pharmacists‟ professional expertise more in areas such as 
costs, interactions, availability and package sizes. Cost-effective prescribing, greater 
use of generics, awareness of drug availability and information on drug 
compatibility are some of the benefits that are observed when pharmacies are 
integrated into healthcare settings when effective collaborative practices occur 
(Howard et al, 2003). Some pharmacists were, however, reluctant to initiate 
interactions that would acquaint general practitioners with their professional 
knowledge.  
 
Matowe et al. (2006) in a more recent study in Kuwait evaluated the perceptions, 
expectations and experience of physicians with hospital-based pharmacists, using a 
hand delivered, piloted self-administered questionnaire. Two hundred physicians 
practicing in 4 government hospitals in Kuwait were recruited to participate in the 
study. The content of the questionnaire was adapted from an existing and validated 
one used in California. Respondents were asked to indicate their level of agreement 
to statements. The significance of association between categorical variables was 
established using the Chi-squared test. The result showed that physicians were 
comfortable with pharmacists carrying out patient-centred roles, except prescribing 
and treating minor illnesses. High expectations existed for pharmacists as 
knowledgeable drug therapy experts to educate patients about the safe and 
appropriate use of medications but their experience showed that pharmacists were 
not sufficiently applying their knowledge in practice. The researchers opined that a 
lack of confidence due to inadequate clinical knowledge could be responsible for 
this underperformance. Also, most of the pharmacists at that time were not familiar 
with Kuwait‟s healthcare system. Similar explanations could also be proposed for 
pharmacists in the English study who were reluctant to initiate interactions to make 
general practitioners aware of their drug knowledge, thereby hindering the process 
of collaboration.  
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2.5.2 GLOBAL TRENDS IN INTER-PROFESSIONAL COLLABORATION 
BETWEEN GENERAL PRACTITIONERS AND COMMUNITY 
PHARMACISTS 
The benefits stated above inform the growing global trend towards collaboration 
between community pharmacists and general practitioners (Woodend, 2003; Bajcar 
et al., 2005; DoH, England, 2008). An increasing number of initiatives are being 
designed to enhance collaboration between the two professions in the delivery of 
healthcare in the community. Bryant et al. (2009) stated that there is a global move 
towards expanding the roles of community pharmacists from the traditional supply 
and distribution to that of increased medicines management services which would 
enable greater involvement in primary healthcare. Inter-professional collaboration 
between general practitioners and community pharmacists is being promoted in 
Europe, North America and Australia (Ministry of Health, New Zealand, 2001; 
DoH, UK, 2003; DoH, England, 2008; Rigby, 2010; Scahill et al., 2010). The 
National Health Service (NHS) in England intended to introduce a system of 
electronic transfer of prescription-related information between general practitioners 
and community pharmacies. Porteous et al. (2003) carried out a study to gather 
opinions of patients (n=800 members of the public), general practitioners (n=200), 
and community pharmacists (n=200), all living in Scotland on this development. 
The survey combined interviews, focus groups, and postal questionnaires. Corrected 
postal response rates were: 69% (patients); 74% (general practitioners); and 74% 
(community pharmacists). The three groups were supportive of electronic transfer of 
prescription-related information. General practitioners acknowledged that it 
improves repeat prescribing; patients expected improved convenience; and 
community pharmacists believed it would enhance their professional role. Concerns 
were however raised about confidentiality of patient records.   
In New Zealand, the United Kingdom, Australia and Canada, the governments and 
professional bodies are initiating and supporting concepts such as patients medicines 
use reviews (MUR) and adherence support programs for patients (Blenkinsopp et 
al., 2007). Bissell et al. (2009) described the experiences of forty-nine patients with 
coronary heart disease in a medicines management service provided by community 
pharmacists in England. Semi structured, face-to-face interviews were employed in 
 
 
 
 
15 
 
the study. Patients carefully accepted consultations from pharmacist about their 
medicines but they were doubtful of the recommendations they made about 
treatment. These concepts are being introduced in a bid to expand the roles of 
community pharmacists so they can play a more active role in primary healthcare 
delivery in collaboration with general practitioners (Scahill et al., 2010; Rigby, 
2010). During the Pharmacy World Congress in Netherlands, the International 
Pharmaceutical Federation and the World Medical Association in a joint statement 
concluded that a patient would be best served if pharmacists and medical 
practitioners collaborate together to ensure that  such a patient gets the best possible 
healthcare (Pharmacy World Congress, Netherlands, 1998). 
2.5.2.1 Need for collaboration between general practitioners and community 
pharmacists 
With increasing scientific, medical and pharmaceutical knowledge, medications 
have become more potent and their use more complex. This is underscored in the 
elderly and patients with chronic illnesses for which current best practices require 
the use of multiple medications (Chobanian et al., 2003; Canadian Diabetes 
Association, 2003; Bajcar et al., 2005). Poly-pharmacy with its associated risk of 
toxicity, which is responsible for side effects, increased health cost and time wastage 
can occur when patients visit independently practicing general practitioners and 
community pharmacists. Doucette et al. (2005) in a study of a comprehensive 
medicines therapy management (MTM) involving a community pharmacist and a 
local medical practitioner concluded that ambulatory patients taking multiple 
medications can have improved drug therapy and subsequently improved health 
outcomes if community pharmacists and general practitioners collaborate. This was 
achieved when community pharmacists monitored and assessed patients‟ medicine 
therapy and made recommendations to the medical practitioner, some of which he 
accepted and utilized (Doucette et al., 2005).  
Medicines meant for therapeutic purposes can have side effects, produce adverse 
reactions, and may interact with other medications, food, or over-the-counter 
medicines leading to adverse events in patients (Lee et al., 2009). Studies have 
shown that the occurrence of medication-related problems in patients could be as a 
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result of inappropriate care from health practitioners such as inadequate monitoring 
of the patient‟s drug therapy (67%), and inappropriate dose (51%), however, poor 
compliance on the patients‟ part can result in poorly controlled health conditions and 
a subsequent surge in healthcare costs (Elliott et al., 2005; Cantrell et al., 2006). 
 
Studies in the United States of America have shown that 6% - 28% of emergency 
visits and hospital admissions are associated with medicine-related problems with an 
associated cost of $177.4 billion and $10.9 billion in Canada (Howard et al., 2003). 
The National Prescribing Service in Australia also identified significant problems 
associated with medication use; approximately 6% of hospital admissions are 
associated with adverse drug events and high error rates during transfer of care 
(Rigby, 2010). Medication errors, most of which are prescription errors are 
responsible for the hospitalization of 1% - 2% of patients in the United States of 
America (Leape et al., 1999). Sanders and Esmail, (2003) affirmed that there is an 
11% chance of errors in all prescriptions and these errors are mainly in the issuing of 
dose and medication selection. Sellors et al. (2003) had a similar observation in 
family practice with prescription errors being more common in areas like medication 
selection, patients not receiving the most appropriate medication and inadequate 
dose of medicines. Roughead et al. (2004) were also in agreement with the above 
observations and added that a third of all the patients in a community setting need 
additional monitoring. 
  
WHO stated that medication non-adherence is a major problem worldwide that has 
become a priority in healthcare research and policy making (WHO, 2003). 
Monitoring of patients‟ adherence to therapy is a crucial role that can be undertaken 
in collaboration by general practitioners and community pharmacists with the 
inclusion of the patient (Macdonell & Jacobs, 2002; Bajcar et al., 2005; National 
Institute for Health and Clinical Excellence, 2009), since the administration of the 
medication is the final and most important step in delivery of healthcare to patients. 
In ambulatory care settings, this important role is the responsibility of the patient 
and the patient‟s care giver (Forster et al., 2004). Studies have shown that between 
20% - 70% of patients do not take their medication as prescribed, or according to 
instructions of the healthcare provider (an approximate average of 50%) and this is 
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most common amongst the chronically ill with long-term medication use (Haynes et 
al., 2001; Horne et al., 2006;  Haynes et al., 2008). In England, it is estimated that 
30% - 50% of prescribed medicines are not taken as recommended and wasted 
medicines cost about £100million per year (DoH, UK, 2008). When medications are 
not taken according to the healthcare practitioners‟ instructions, the desired health 
gains cannot be observed. Sullivan et al. (1990) had earlier estimated that 5.3% of 
hospitalizations were due to medication non-compliance but Howard et al. (2003) 
observed a higher percentage (30%) of patients being admitted to medical units due 
to non-adherence to prescriptions. Medication non-adherence has also been shown 
to result in hospital admissions (30-35%) for preventable adverse drug reactions 
(MacDonell & Jacobs, 2002). Patients need to understand their medical illness and 
have adequate knowledge and understanding of their medication, particularly with 
respect to how it would improve their health so as to effectively self-regulate their 
medication taking practices according to the prescription of the healthcare giver 
(Dowell & Hudson, 1997; Bajcar et al., 2005). Gilbert et al. (2004) observed that 
lack of knowledge about the medications being used was related to 20% of the 
medicines related problems identified in the community setting. Kennie and Bajcar, 
(2002) had more disturbing observations in a medication check-up program where 
92% of patients with medication related problems did not fully understand their 
medication and half of them had additional questions they wanted to ask about their 
medications. Medication reviews carried out by community pharmacists in 
residential aged care facilities have been useful in this area (Baran et al., 1999).  
More than fifty per cent of medicine related problems and their consequences are 
believed to be preventable through collaborative patient management between 
community pharmacists and general practitioners. This would enhance patients‟ 
therapeutic outcomes and reduce the considerable medication-related morbidity and 
mortality reported (MacDonell & Jacobs, 2002; Howard et al., 2003). 
With overburdened public healthcare systems that are still facing pressure to reduce 
cost while maintaining or improving quality of healthcare, an increasing ageing 
population due to longer life expectancy, and a greater burden of chronic diseases, 
collaborative patient care between community pharmacists and general practitioners 
offers a means of relief from these demands (Howard et al., 2003; Rigby, 2010). 
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2.5.2.2 Benefits of inter-professional collaboration between general 
practitioners and community pharmacists 
Collaboration between general practitioners and community pharmacists could 
improve patients‟ health outcomes (Blenkinsopp et al., 2000; Raynor et al., 2000; 
Clifford et al., 2006; Dolovich et al., 2007; Elliot et al., 2008). Integration of 
pharmacists in direct patient-care has yielded benefits and resulted in better 
medication management in Australia and Europe (Clifford et al., 2010). Professional 
cohesion and enhanced patient care have been achieved by reviews of patient 
medicine use carried out by community pharmacists in collaboration with general 
practitioners in the United Kingdom and New Zealand (Bradly et al., 2008a; Lee et 
al., 2009a). General practitioners in Canada have accepted collaborative practice as 
they have come to understand the advantages of working with pharmacists (Pottie et 
al., 2008; Farrell et al., 2008). Collaborative models have improved the treatment of 
hypertension (Carter et al., 2009), diabetes (Wermeille et al., 2004), and 
hyperlipidaemia (Lee et al., 2009) through better medication management and 
improved pharmaceutical care. With improved collaborative practices between 
prescribers and community pharmacists, drug therapy can be optimized through the 
recommendation of solutions to identified medication- therapy problems (Sellors et 
al., 2003; Dolovich et al., 2007).  
Another of such benefits can be seen in an asthma-management multidisciplinary 
intervention educational study conducted at the University of Tasmania, Australia.  
This study demonstrated that engaging pharmacists more completely in the care of 
patients‟ reaps large benefits in terms of health outcome. Bereznicki et al. (2008) 
used a multi-site controlled study design; forty-two pharmacies were recruited 
throughout Tasmania to run a software application that "data-mined" medication 
records and generated a list of patients who had received three or more canisters of 
inhaled short-acting beta (2)-agonists in the preceding 6 months. Identified patients 
were allocated to an intervention or control group. Pre-intervention and post-
intervention data were collected. Patients considered to require intervention were 
contacted via mails, sent educational materials and encouraged to visit their general 
practitioner for an asthma management review. This intervention resulted in a three-
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fold increase in the ratio of preventer-to-reliever users in the intervention group (P < 
0.01) compared with the control group. Hence, fewer patients were reliant solely on 
reliever medication and patients were educated and encouraged on more appropriate 
use of preventers (Bereznicki et al., 2008). 
In Hong Kong, Lee et al. (2009) showed that a pharmacist–physician co-managed 
program for hyperlipidaemia effectively assisted patients in reaching target lipid 
levels. The study was a prospective randomized controlled trial. 118 adult patients 
were selected if (i): they were taking one or more lipid-lowering agents with a valid 
lipid panel before their next follow up; (ii) had a baseline lipid profile within the 
previous 6 months; (iii) their lipid panel did not reach the targeted low-density 
lipoprotein-cholesterol (LDL-C) goal based on the National Cholesterol Education 
Programme Adult Treatment Panel III. 58 patients were in the intervention group 
(mean age 63 +/- 10 years old) while the control group had 60. Patients in the 
intervention group were interviewed by pharmacists for 15 to30 minutes after their 
usual clinic visit and counselled on the drug regimen and possible life style changes. 
Also, follow-up telephone calls were made every 4 weeks and follow-up interviews 
on the date of the physician visit were scheduled. Patients in the control group 
received routine conventional care. A (statistically significant) higher, low-density 
lipoprotein-cholesterol (LDL-C) and total cholesterol levels were observed in the 
control group compared to the intervention group (P < 0.0015). 
2.5.2.3  Benefit of inter-professional collaboration between general practitioners     
and community pharmacists: the  south African context  
The burden of diseases in South Africa is almost double that of developing 
countries, and on average four times larger than that of developed countries 
(DALY‟s) [NHI notes 2, 2009]. South Africa, in particular, is said to have a 
„quadruple‟ burden of disease based on the results of its mortality profile and 
disability-adjusted life-years (DALY‟s) [NHI notes 2, 2009]. This is the case 
because most developing countries experience a double burden of disease resulting 
from the concomitant presentation of communicable and non-communicable 
diseases in the population, while developed countries have graduated from 
communicable diseases to degenerative, chronic diseases. South Africa on the other 
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hand, in addition to the occurrence of communicable and non-communicable 
diseases, experiences the added burden of injuries, perinatal and maternal diseases 
and a high incidence of HIV/AIDS (Norman et al., 2006). According to a WHO 
estimate, South Africa‟s burden of non-communicable diseases is two to three times 
higher than that in developed countries, and it includes chronic diseases such as 
cardiovascular disease, type 2 diabetes, certain cancers, chronic lung disease and 
depression (Househam, 2010). South Africa can be said to be in the middle of a deep 
health transition due to social, economic and behavioural factors (Mayosi et al., 
2009).  
 
This situation exerts a larger burden on human resources particularly in the already 
deficient health sector. The economic implications are also immense compared to 
other countries. Some of the strategies being put in place to manage the burden of 
disease were emphasized in the National Burden of Disease Study. These are: to 
strengthen public health, build evidence base and improving surveillance data that 
are needed to promote health and prevent diseases, in addition to the need for the 
provision of a wide range of health services (DoH, South Africa. 2011). 
 
The human resource shortages being experienced in the public health sector are 
being aggravated by the quadruple burden of disease experienced in the country, 
leaving the already strained and under-resourced nurses, doctors and pharmacists 
more despondent. Given the higher number of general practitioners (7.64/4.52 per 
10,000 total population in the private/public sectors) and pharmacists (11.17/1.93 
per 10,000 total population in the private/public sectors) in the private health sector 
than in the public health sector, pooling resources from the private sector health 
work force is also one of the strategies being proposed to manage the burden of 
disease and improving healthcare delivery (DoH, South Africa. 2011). 
A majority of the patients do not visit public hospitals and clinics for preventive 
purposes, but rather for curative purposes. In South Africa and other parts of the 
world, private pharmacies are among the first ports of call for clients with minor 
ailments (Gilbert, 1998). With such patronage, the task of health promotion through 
public health education; one of the professional roles of the community pharmacists 
can be more effectively carried out in collaboration with general practitioners. 
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 With increasing life expectancy, more people are living with chronic illnesses for 
longer periods of time. Chronic diseases are projected to account for equal numbers 
of deaths as communicable, maternal, perinatal, and nutritional diseases by 2020 
(Mcleod, 2011; WHO, 2011). Community pharmacists are presently involved in 
filling repeat prescriptions for chronic illnesses for up to six months and referring 
the patient back to the doctor if a need arises. As interventions in other countries 
have shown, with improved inter-professional collaborative practices or 
relationships between general practitioners and community pharmacists, patients are 
assured of better health services and consequently improved therapeutic outcomes. 
Results of blood pressure readings, fasting blood glucose levels and other minor 
tests which are already being done in pharmacies can be sent directly to the general 
practitioner.  Medication management is another area where community pharmacists 
have been found to be very useful in collaboration with general practitioners, since 
they review patients‟ medication histories for a more effective outcome. These 
services result in reduced medication costs (Bond et al., 2000), quick identification 
of medication problems (Pharmacy Flyer. Issue 7, 2001) and increased monitoring 
of medication adherence (Hughes et al., 2000). 
 
Minor and self-limiting illnesses such as colds, flu, and head lice can also be 
managed by the community pharmacist and help can be sought from the general 
practitioner if the need arises with the existence of a good relationship between them 
(Hassell et al., 2001; Blenkinsopp A, 2003; Hammond et al., 2004; DoH, England. 
2006). This would reduce unnecessary strain on the general practitioner and enable 
him to focus on more serious health conditions (Dowell et al., 1998; National 
Prescribing Centre, 2002; Cabinet Office Regulatory Impact & DoH, 2002). This 
would also save the patients cost for private consultations and waiting time 
especially in public health facilities. Up to 2.7 million hours of general practitioners‟ 
time and practice hours were saved in England through the minor ailment scheme 
and repeat prescriptions undertaken by community pharmacists (National 
Prescribing Centre, 2004; DoH, UK. 2003). Both patients and general practitioners 
were found to be in support of these services (New Pharmacy Contract in England, 
2005; Porteous & Bond, 2005). 
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The National Health Insurance (NHI) being introduced in South Africa is a system 
of healthcare financing that is meant to ensure that everyone has access to 
appropriate, efficient and quality health services. A Green Paper outlining the policy 
on NHI from the Department of Health stated that reforms that would improve 
service provision are expected to accompany the NHI such that all South Africans 
can have access to affordable, quality healthcare services regardless of their socio-
economic status similar to the WHO definition of primary healthcare (WHO, 1978).  
The present inequitable healthcare delivery system obtainable in South Africa would 
need to be overhauled for successful implementation of the NHI (DoH, South 
Africa. 2011a). With this in view, a comprehensive package of healthcare supported 
by a re-engineered primary healthcare is being planned (DoH, South Africa. 2011). 
The Department of Health‟s paper in section 4.2.1 under  priority workforce 
implications for re-engineering primary healthcare, task shifting and defining new 
roles states that the scope of practice of all healthcare practitioners would need to be 
reviewed and revised to maximize available human resources. As stated earlier, the 
pooling of human resources from the private health sector is one of the strategies for 
the rejuvenation of the health system. The paper proposes re-establishing the role of 
the private general practitioner in primary healthcare as an important clinical care 
and teaching role. Role redefinitions and extensions are proposed for current 
enrolled nurses while the competencies of pharmacist assistants are going to be 
increased. Although no mention is made in this paper of community pharmacists or 
the roles they play in primary healthcare, the recent publication of the „Authorized 
Pharmacists Prescriber‟ qualification and scope of practice in the Government 
Gazette no 34428 attest to the recognition of the roles pharmacists can play in 
primary healthcare (South African Pharmacy Council, 2011). Pharmacists who have 
been trained and have qualified to practice as „Authorized Prescribers‟ can help to 
meet the healthcare needs of the country in line with the WHO recommendations for 
primary healthcare standard treatment guidelines (STG) and essential medicines list 
(EML). This role extension would integrate and enhance the role qualified 
community pharmacists play in primary healthcare as a precursor to their inclusion 
in the proposed NHI as is observed in some other countries with national health 
financing schemes (South African Pharmacy Council, 2011). 
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2.6 PROCESS OF COLLABORATION BETWEEN GENERAL 
PRACTITIONERS AND COMMUNITY PHARMACISTS  
Collaboration would not be automatically effected in any system without an external 
or internal force. There are more factors that hinder than support collaboration 
between general practitioners and community pharmacists. One of such factors is the 
nature of community pharmacy practice that is characterized as a business premises.  
Therefore, community pharmacists are often not regarded as a core part of the 
primary healthcare team. There is a general perception by other healthcare 
professionals, funders and consumers around community pharmacists being traders 
rather than healthcare providers (Hughes & McCann, 2003; Rigby, 2010). The 
introduction of private consulting areas in community pharmacies where patients 
can have privacy to discuss personal issues with pharmacists is one of the solutions 
to the image crisis of community pharmacy practice. Another factor militating 
against collaboration between general practitioners and community pharmacists is 
geographical separation and isolation of premises. Interactions with general 
practitioners are brief and most probably telephonically. Co-location of practices 
would help overcome this barrier. Lack of access to patients‟ medical records is also 
a barrier acknowledged by general practitioners but the introduction of electronic 
health records may potentially overcome this barrier as well as educate the patient to 
appreciate collaboration.  
McDonough and Doucette, (2001) proposed a model for establishing collaborative 
working relationships (CWR) between general practitioners and community 
pharmacists, which describes the stages that relationships need to go through before 
commitments can be made between practitioners to have a collaborative practice 
agreement (CPA). They categorized the characteristics that influence collaboration 
as participant, context and exchange characteristics which describe the elements 
essential to collaboration mentioned earlier in this review. They emphasized that for 
collaboration to occur community pharmacists would have to initiate it. In the CWR 
model, the first two stages (0 and 1) are pharmacist-initiated and communication is 
unilateral; these are the professional awareness and professional recognition stages. 
Stage 2 is the professional exploitation and trial stage; here practitioners test their 
compatibility, trustworthiness and commitment to the relationship. Stage 3 is the 
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professional relationship expansion stage when communication becomes bilateral 
but is still unbalanced as pharmacists need to do most of the communication. The 
relationship is being fine-tuned, conflicts might arise and performance assessments 
characterize this stage. Stage 4 describes the commitment to the collaborative 
working relationship. Physicians would rely on the pharmacists‟ exhibited 
knowledge and skills while pharmacists rely on the exchange of patients‟ clinical 
information. An equitable relationship is established if exchanges and relative power 
between practitioners are balanced. This model was used in this thesis to determine 
the stage of collaboration between general practitioners and community pharmacists.   
 
Pojskic et al. (2009) observed the infrequent collaboration that occurs between 
Ontario family physicians and community pharmacists on drug therapy 
management. They proceeded to assess the attitude and readiness of 848 randomly 
sampled Ontario community based general practitioners to collaborate in this area 
using a three-page questionnaire.  Participants were selected from the 2006 
electronic version of the Canadian Medical Directory. The study focused on findings 
relating to communication between general practitioners and community 
pharmacists, the extent of collaboration between the two, and perceptions of the 
advantages, disadvantages and barriers to collaboration. General practitioners‟ 
readiness to collaborate was evaluated on 3 specific behaviours that correspond to a 
continuum of collaboration: taking pharmacists‟ phone calls (low-level), seeking 
pharmacists‟ recommendations regarding patients‟ drug therapy (mid-level) and 
referring patients to pharmacists for medication reviews (high-level). Results 
confirm that low-level collaborations occur between general practitioners and 
community pharmacists because most general practitioners had 5 or fewer 
conversations a week with a community pharmacist about a patient‟s drug therapy 
management, very few used pharmacists as their primary source of medication 
information and few participated in higher-level collaborative behaviour (referring 
patients to pharmacists for medication reviews). Despite the result, general 
practitioners had a good attitude toward collaboration. An explanation that was 
offered for the low-collaboration observed in the study was that general practitioners 
were not aware that community pharmacists conducted medication reviews. It was 
concluded that community pharmacists need to make general practitioners aware of 
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their expanded roles through more frequent interactions which would need to be 
initiated by community pharmacists according to the CWR model proposed by 
McDonough and Doucette, (2001).  
 
The influence of perception on collaboration was assessed in a study conducted in 
New Zealand where community pharmacists were expected to carry out clinical 
services such as medication management which would require collaboration with 
general practitioners. Bryant et al. (2009) opined that differing role perceptions 
between general practitioners and community pharmacists are likely to hinder the 
effective delivery of this service and consequently, collaboration. One thousand 
randomly selected general practitioners and 900 community pharmacists were sent a 
postal survey which contained questions regarding the pharmacist‟s roles in 
community healthcare and barriers to collaboration. Responses to the questions were 
scored using Likert scale ranking ranging from 1 for “definitely yes” to 5 for 
“definitely no”. Factor analysis was used to categorize the questions pertaining to 
barriers to providing medicines management. A significant difference was observed 
in the perceptions of community pharmacists and general practitioners regarding the 
role of community pharmacists in healthcare delivery. Both groups acknowledged a 
more traditional role for community pharmacists, but general practitioners were not 
in agreement with the clinical roles of medicines management. Barriers that were 
observed to hinder medicines management included: lack of mandate to undertake 
the services, the role was not a legitimate community pharmacist role, possession of 
adequate knowledge or skills to perform the service, and doubts that the service 
would improve patients‟ health outcomes. Another factor that became obvious in 
this study is community pharmacists‟ lack of confidence in their clinical skills to 
carry out the service. Self-confidence is an element that is necessary for effective 
collaboration. For role expansion to be successful, community pharmacists need to 
exhibit more confidence and competence in clinical issues through continuous 
education. In the United States and the United Kingdom, post graduate residencies 
and training are organized by pharmacy schools and professional bodies to improve 
competency in clinical issues. 
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One of the competencies mentioned in this review is the willingness to collaborate 
(D‟Amour & Oandasan, 2005; D‟Amour et al., 2005). Community pharmacists need 
to exhibit this competence. It has been proven in the course of this review that 
effective collaboration with general practitioners is feasible only with role 
expansion. It has also been obvious from reviewed studies that community 
pharmacists are reluctant to enlighten general practitioners about their professional 
skills. From the history of the role expansion and evolution observed in the nursing 
profession in the United States of America (USA), UK, and most parts of the world 
where complementary and needs-led skill mix models have led to complementary 
nurse-doctor hybrid roles that we observe today in the nursing profession, this 
expansion was initiated from within the profession itself in the USA (Keyzer, 1997). 
Therefore, a similar trend might be required for expansion of roles to be achieved in 
community pharmacy practice. 
  2.7 OVERVIEW OF LITERATURE REVIEW 
The need for and benefits of inter-professional collaboration between general 
practitioners and community pharmacists is supported by literature from a global 
angle. The immense advantage to the South African healthcare system with the 
prevalent unusual burden of communicable and  non-communicable diseases, 
maternal and perinatal diseases, injuries and a very high incidence of HIV/AIDS, 
which create a strain on the already personnel deficient healthcare system,  is 
undeniable. Inter-professional collaboration can be particularly beneficial to South 
Africa in the area of preventive healthcare or health promotion, and as co-
management of chronically ill patients can reduce the mortality and disability caused 
by these chronic conditions. The introduction of the NHI is another reason why 
collaborative practices between general practitioners and community pharmacists 
need to be encouraged. The recent publication of the scope and qualification of the 
„Authorized Prescriber Pharmacists‟ attest to the recognition of the role of 
pharmacists in primary healthcare. This role extension can be used as a platform to 
enhance collaboration between community pharmacists and general practitioners. 
The CWR model proposed by McDonough and Doucette, (2001) was used in 
determining the stage of collaboration. Other factors that influence collaboration 
such as general practitioners‟ perceptions of community pharmacist roles and 
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general practitioners attitudes towards collaboration with community pharmacist 
were assessed in this thesis.   
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CHAPTER THREE 
RESEARCH AIM AND OBJECTIVES 
3.1 INTRODUCTION 
The aim and objectives of this thesis are expressed in this chapter. The research 
questions developed to achieve these aim and objectives are also presented. 
3.2 RESEARCH AIM 
The primary aim of this thesis is to determine from general practitioners‟ 
perspectives, the extent of inter-professional collaboration between general 
practitioners and community pharmacists in patients' care in the Cape Metropole of 
South Africa.  
3.3 RESEARCH OBJECTIVES 
The objectives of this thesis are to determine and describe the following from the 
perspectives of general practitioners in the Cape Metropole: 
1. To determine and describe general practitioners‟ perceptions of the 
professional roles of community pharmacists in patients care (Cape Town, 
South Africa). 
2. To determine and describe the attitudes of general practitioners toward 
collaboration with community pharmacists in patient care. 
3. To determine and describe the level of current collaboration between general 
practitioners and the community pharmacists in Cape Town, South Africa. 
4. To determine and describe the perceived barriers to collaboration between 
general practitioners and community pharmacists in patient care. 
5. To determine and describe the areas of patients‟ care where general 
practitioners would like to collaborate with community pharmacists in the 
future. 
6. To determine and describe how general practitioners‟ demographic 
characteristics influence inter-professional collaboration with community 
pharmacists. 
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3.3.1  RESEARCH QUESTIONS 
The following research questions were formulated to achieve the research aims 
and objectives of this study: 
1. What is the current level and stage of collaboration between general 
practitioners and community pharmacists in patient care from the general 
practitioners‟ perspectives? 
2. Do general practitioners‟ perceptions of the professional roles of community 
pharmacists in patients‟ care influence the desired collaboration (prospects of 
enhanced future collaboration) between general practitioners and community 
pharmacists in patient care? 
3. Do general practitioners envision enhanced future collaboration between 
them and community pharmacists in patient care and if so, what does this 
entail? 
4. What are the barriers to the envisioned collaboration between general 
practitioners and community pharmacists in patient care? 
5. Do general practitioners‟ demographic characteristics influence inter-
professional collaboration with community pharmacists? 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
CHAPTER 4 
RESEARCH DESIGN AND METHODOLOGY 
 
4.1 INTRODUCTION 
 
This chapter presents the research design and the methods by which the design was 
executed. The chapter consists of 12 sections beginning with introduction, study 
area, study population, study design, sampling strategy and selection criteria, 
recruitment strategy and data collection, measurements, research variables, 
statistical issues and ethical consideration. This chapter would also examine the 
limitations of the study and end with a brief summary. 
 4.2 STUDY DESIGN 
The study was based on a quantitative and qualitative (mixed methods), descriptive 
and correlational, and cross-sectional survey. It was designed to measure possible 
associations between variables within a single sample of a population, from data 
collected on a single occasion. Though it employed a mixed method design, 
qualitative method was employed for the purpose of expansion or supporting 
collected quantitative data (Rossman & Wilson, 1985; Denzin & Lincoln, 2005). 
The qualitative method was limited in its scope as the instrument was used 
comprised only of two open ended questions (Appendix III). Quantitative methods 
are usually used in isolating and identifying correlations between variables; 
qualitative techniques are particularly good at gaining insight into the processes and 
events that might lead up to the observed variation and has the key advantage of 
providing unexpected insights (Hoff et al., 2000). The study combined the 
advantages of both methods especially as the qualitative data was not quantized but 
discussed. As such, the disadvantages that apply to transformative mixed method 
designs do not apply here.  
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4.3 STUDY AREA 
The study was carried out in the Cape Metropole, a district in the Western Cape 
Province of South Africa. The Cape Metropole includes the city of Cape Town. 
Approximately 10% of South Africa‟s population resides in this province, of which 
nearly 80% find domicile in the urbanized Cape Metropolis (Baron et al., 2006). The 
province is also home to the highest number of medical practitioners (5.67 per 
10,000 total population) with a higher number of them working in the private sector 
(7.6 per 10,000 total population) [DoH, South Africa. 2011]. This makes it a most 
suitable choice for an accessible population in the study. It is geographically divided 
into 8 suburban areas, namely: Southern Suburbs, Northern Suburbs, South 
Peninsula, Cape Flats, West Coast, Atlantic Seaboard, Heldelberg and City Bowl. 
The suburban demarcation of the Cape Metropole was used to ensure proportionate 
selection of general practitioners from each suburb across the area. 
4.4 STUDY POPULATION  
The target population for this study was general medical practitioners in private 
practice in the Cape Metropole. This is because the study was designed to focus on 
the general practitioners‟ perspectives of inter-professional collaboration with 
community pharmacists, because of the numerous advantages that such 
collaboration might have on patients‟ health outcomes as enumerated in chapter two. 
Findings would be inferred to general practitioners in South Africa. 
4.5 SAMPLING STRATEGY AND SELECTION CRITERIA 
4.5.1 SAMPLING STRATEGY 
The sampling strategy defines the basis used for the selection of participants from 
the population of interest such that the study results can be generalized back to the 
population. 
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4.5.1.1 Stratified random sampling 
A list of general practitioners in the Cape Metropole was obtained from the South 
African Medical Association (SAMA). The Health Professions Council of South 
Africa (HPCSA) could not provide the researcher with a list of private general 
practitioners based in the Cape Metropole from its database according to a mail 
received from its office in which it also advised that the information could be 
obtained from SAMA. The list contained 1214 names, of which only 888 could be 
included in the survey because they had both their physical or postal addresses and 
phone numbers that were included on the list or were in the Cape Town 2010 
telephone directory. The names were stratified into the eight suburban classifications 
of the Cape Metropole using the postal codes of members obtained from the list. 
These strata had unequal populations [Southern peninsula (n= 42), Atlantic 
Seaboard (n=60), West Coast (n=60), Cape Flat (n=138), Southern Suburbs (n=270), 
and Northern suburbs (n=303)], as such, a sampling fraction, f (Trochim, 2006) was 
used to randomly sample from each of the strata (suburban area) at proportional 
ratios of the required sample size.  
Sampling fraction, f = N/n 
Where, 
n= the number of cases in the sampling frame (888)  
N= required sample size (52) 
f = N/n =0.059 
The stratified population in each suburban area was multiplied by the sampling 
fraction to obtain a proportional ratio of general practitioners from each area. 
Southern peninsula (n= 2), Atlantic Seaboard (n=4), West Coast (n=4), Cape Flat 
(n=8), Southern Suburbs (n=16), and Northern suburbs (n=18). The stratified sample 
was randomized using Excel Microsoft Word 2003 (MS2003) [Trochim, 2006]. 
Randomized sampling was used because it offers a scientific basis for making 
inferences about the results to the general population (Hulley et al., 2007:117). 
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Stratified random sampling was also chosen because it has better statistical precision 
than simple random sampling (Trochim, 2006). 
4.5.2 SELECTION CRITERIA 
This selection criteria defines the conditions required for participation and non- 
participation in the study as: inclusion and exclusion criterion respectively. 
4.5.2.1 Inclusion criterion 
Eligible participants were registered general practitioners within the Cape Town 
Metropolis of South Africa who had physical or postal addresses and phone numbers 
included on the SAMA membership list (refer to section 3.6.1.1) or listed in the 
Cape Town 2010 telephone directory. 
4.5.2.2  Exclusion criterion 
Registered general practitioners whose physical or postal addresses and phone 
numbers were neither on the list obtained neither from SAMA nor in the Cape Town 
2010 telephone directory. 
4.6 RECRUITMENT STRATEGY AND DATA COLLECTION 
The strategy used to select the participants for the study and the method of data 
collection is discussed in this section. 
4.6.1 RECRUITMENT STRATEGY  
An introductory letter (appendix I) was mailed to general practitioners informing 
them of the aims and procedures of the study. A follow-up telephone call was made 
a week after mainly to ascertain if the letters were received and to further discuss the 
study as well as answer any questions from the participants. Participants were again 
informed that consultation fees would be paid for time expended on the study as 
indicated in the introductory letters. Appointments were made with assenting 
general practitioners for the completion of questionnaires and consent forms. 
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Some challenges were encountered during the recruitment stage of the study. For 
example, some of the general practitioners did not receive the introductory letter 
initially mailed to them because the addresses obtained from SAMA wes wrong, as 
stated earlier. Hence, the study had to be introduced to them telephonically. As such, 
some of them required more time and more telephone calls to make up their minds 
about participation in the study thereby extending the study period. Some general 
practitioners were unreachable telephonically despite the availability of their phone 
numbers and addresses. Others, whose surgeries were contacted telephonically, were 
too busy to engage the researcher in a conversation. One had passed away, others 
had retired, migrated or were no longer practicing as general practitioners. These 
resulted in a need to over sample to be able to achieve the required sample size.  
The introduction of consultation fees could positively or negatively bias the results 
of the survey. Studies have shown that item non- response, data quality and 
willingness to participate are biases associated with the introduction of incentives in 
surveys (Singer, 2006). The offer of a consultation fee was not enough to convince 
some general practitioners to participate in the present study. 
4.6.2 DATA COLLECTION 
A face-to-face self-administered method was employed for data collection. Consent 
forms (appendix II) were given to the participants to bet signed; questionnaires were 
then completed by participants over a 20 minute period and returned to the 
researcher. This method was employed firstly, to increase participation as most 
studies on collaboration between general practitioners and community pharmacists 
had used the mail or (and) fax survey method and focus groups which were 
associated with poor responses (Pojskic et al., 2009; Bryant et al., 2009; Hughes et 
al., 2003). Secondly and most importantly, the face to face method allows the 
researcher to gather qualitative data from suggestions and comments made by 
participants which was thought to be important in improving the relationship 
between general practitioners and community pharmacists in South Africa. 
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4.7 MEASUREMENTS 
The study measuring instrument, the criteria used for selecting the different 
components of the instrument and discussion on the contents of the measuring 
instrument are presented below. 
4.7.1 MEASURING INSTRUMENT 
 
A self-administered questionnaire was constructed with closed and open-ended 
statements (appendix III); responses were analysed as quantitative and qualitative 
data, respectively. The questionnaires addressed specific factors that influence inter-
professional collaboration as observed from previous studies on inter-professional 
collaboration between general practitioners and community pharmacists. It consists 
of six sections containing items measuring the demographic characteristics of 
participants, general practitioners‟ perceptions of the professional roles of 
community pharmacists, general practitioners‟ attitudes to collaboration with 
community pharmacists, current collaboration in practice, barriers to collaboration 
and prospects of enhanced future collaboration. One open-ended question was each 
included under the sections for barriers to collaboration and prospects of enhanced 
future collaboration for qualitative data collection. The prospects of enhanced future 
collaboration section were designed by the researcher entirely while the other 
sections had inputs from instruments used in similar studies and literature on the 
same topic.  
4.7.2 SELECTION AND CONTENT 
Items in sections one, two and five of the instrument were constructed from existing 
instruments used in similar studies of inter-professional collaboration between 
general practitioners and community pharmacists as well as literature on the same 
topic (Hughes & McCann, 2003; Dobson et al., 2006; Wiedenmayer et al., 2006; 
Bryant et al., 2009; Pojskic et al., 2009; Rigby, 2010). In addition to some items in 
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sections three and four being constructed from similar existing instruments, items in 
these sections were structured to fit the different stages of the Collaborative 
Working Relationship (CWR) model proposed by McDonough and Doucette, 
(2001). These items were structured in such a way that the stage of collaboration 
could be determined. The process of selection of the items in each section is 
discussed below.  
4.7.2.1   Collaborative working relationship (CWR) model 
The CWR model proposed by McDonough and Doucette, (2001) is a conceptual 
model of team building between physicians and pharmacists. It describes the 
different stages of relationships that a team undergoes before becoming highly 
functional. Given that one of the aims of the study is to determine if inter-
professional collaboration occurs between general practitioners and community 
pharmacists and the extent to which this occurs, the model serves as a tool that can 
be used to measure the stage of collaboration between general practitioners and 
community pharmacists who are building successful working relationships. Bradley 
et al., (2010) described the CWR model as the most developed with respect to 
general practitioners-community pharmacists‟ specific models in USA. The model 
has been used in several studies the world over to examine collaborative practices 
between general practitioners and community pharmacists and it has been stated to 
be an effective and practical model for establishing collaboration between the two 
professions (Doucette et al., 2005; Farris, 2005; Zillich et al., 2006; Pojskic et al., 
2009). The model consists of five stages of development from professional 
awareness to the stage where collaborative practice agreements (CPA) are 
established between the parties or formalized arrangements for care of patients are 
made. The stages are: 
Stage 0--------- Professional Awareness 
Stage 1---------- Professional Recognition 
Stage 2---------- Exploration and Trial 
Stage 3---------- Professional Relationship Awareness 
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Stage 4---------- Commitment to the Collaborative Working Relationship 
 
4.7.2.1.1 Stage O collaboration (Professional Awareness) 
This is the first stage of the CWR model which signifies the least level of 
interactions observed between community pharmacists and general practitioners. 
Interactions are of a discrete nature such as dispensing prescriptions that are faxed or 
telephoned to the pharmacy, identifying adverse drug interactions and answering 
drug information questions. 
4.7.2.1.2 Stage 1 collaboration (Professional Recognition) 
This is the second stage of the CWR model. Exchanges at this stage are usually 
initiated by the pharmacists and the frequency and direction of interactions tend to 
be unilateral. The resourcefulness of community pharmacists to provide services 
relevant to general practitioners‟ practices is exhibited here.  Such services include 
the provision of patients‟ medication histories, adherence information or introducing 
a new service that would benefit patients and the targeted general practitioners. 
4.7.2.1.3 Stage 2 collaboration (Exploration and Trial) 
General practitioners assess and test the compatibility, expectations, trustworthiness 
and commitment of community pharmacists to the relationship (Dwyer et al., 1987) 
especially where a new service is being introduced by the pharmacists.  Patients 
might be referred to community pharmacist for the service to test these 
characteristics. 
4.7.2.1.4 Stage 3 collaboration (professional relationship expansion) 
If general practitioners benefit from the exploration and trial stage of the CWR, they 
can increase interdependency and expand professional relationships (Dwyer et al., 
1987). Key exchange characteristics of this stage include communication, norm 
development, performance assessment and conflict resolution. Exchange of patients‟ 
clinical information is a good sign of successful stage 3 collaboration.  
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4.7.2.1.5 Stage 4 collaboration (commitment to the collaborative working   
relationship) 
At this stage, the input by both parties should be equitable, lengthy and consistent 
(Scanzoni, 1979). General practitioners rely on the knowledge and skill displayed by 
community pharmacists who in turn rely on the clinical information provided to 
manage patients‟ drug therapy. Same exchange characteristic as in stage 3 are 
required here. Plans should be put in place to optimize the joint care of patients                           
(Weitz & Jap, 1995). 
4.7.2.2          Personal information of general practitioners 
The demographics of general practitioners such as age, gender, years in practice, 
nature of practice, and number of patients seen per day were collected. These 
participant‟s characteristics are components that affect the development of a 
collaborative working relationship (Brown, 2006:185). 
4.7.2.2.1 Anticipated effects of predictors 
The influence of general practitioners‟ age and the number of years in practice on 
their perceptions of professional roles of community pharmacists, attitudes towards 
collaboration, current collaboration, prospects of enhanced future collaboration, and 
barriers to collaboration might be due to increasing ability to appreciate the roles of 
the community pharmacists with more experience in practice (Adepu & Nagavi, 
2006). Bryant et al. (2009) in a study on collaboration between general practitioners 
and community pharmacists found differences in the responses from participants 
based on gender. Ward et al. (2003) also came out with a similar conclusion from 
their study. The influence of the nature of practice, categorized into dispensing and 
non-dispensing doctors on collaboration would make an interesting study 
considering the backdrop of dispute between community pharmacists and general 
practitioners in South Africa and other parts of the world (Gilbert, 1998; Royal 
Pharmaceutical Society, 2007). The number of patients seen in a day determines 
how busy a general practitioner‟s schedule is and might also influence interest in 
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inter-professional collaboration (Adepu & Nagavi, 2006). Location of study 
participants‟ practice was exempted from analysis as the practice locations were not 
pre-selected but obtained by default from the list obtained from SAMA as earlier 
explained in section 3.4. 
4.7.2.3  General practitioners’ perceptions of the professional roles of 
community pharmacists  
Fifteen items were used to measure general practitioners‟ perceptions of the 
professional roles of community pharmacists (appendix III). Two of the roles; 
carrying out x-rays and ultra sound scans, and carrying out surgical procedures were 
only included to assess the level of concentration of the participants. In this regard, 
their roles can be termed as irrational roles which should explain why they are 
excluded from the analysis. The thirteen items (See table 1) that were left, were 
selected from a list of community pharmacists roles obtained from the literature on 
general practitioners and community pharmacists (Wiedenmayer et al., 2006; Bryant 
et al., 2009; Rigby, 2010). The section consists of both traditional and advanced 
roles of community pharmacists. Four-point Likert scale response options ranging 
from 1-for “Strongly Disagree” to 4-for “Strongly Agree” were used to measure the 
levels of agreement to the items relating to pharmacist roles. The variable, “general 
practitioners‟ perceptions of professional roles of community pharmacists” was 
computed from the total sum of scores of the Likert scale and depicted in three ways 
as: 1) Good Perceptions, 2) Fair Perceptions, and 3) Poor Perceptions. Likert scale 
response options were assigned these additional labels to better qualify the variable 
as seen in Table 2. “Strongly Agree” Likert scale response option was equivalent to 
“Good Perceptions”, “Agree” Likert scale response option was equivalent to “Fair 
Perceptions”,  “Disagree and Strongly Disagree” Likert scale response options were 
collapsed and summarized as “Poor Perceptions”. 
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Table 1: Thirteen-item scale on professional roles of community pharmacists 
 
Roles 
Strongly 
Agree Agree Disagree 
Strongly 
Disagree 
i. Dispensing prescribed medicines 
to the public     
ii. Providing information to patients 
on prescribed medicines    
 
 
iii. Checking patients‟ prescriptions 
for indications, safety and 
therapeutic duplications     
iv. Reporting adverse reactions to 
drugs to prescribers and health 
authorities     
v. Advising on the cost effectiveness 
of medicines for disease states     
vi. Monitoring patients‟ adherence 
with therapy and ensuring their 
medicine related needs are met      
vii. Monitoring blood pressure, 
blood glucose levels and cholesterol 
levels      
viii. Be a source of clinical advice to 
general practitioners, such as 
selection of a medicine for a 
particular disease state      
ix. Be a source of clinical medicines 
information to general practitioners 
such as adverse effects of medicines       
x. Make dose adjustments to a 
patient‟s medicines using protocols     
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established with prescribers (e.g. 
inhaled steroids in asthma) 
xi. Supervising repeat prescriptions 
for a patient, according to agreed 
protocols, for up to 6 months, 
contacting the general practitioner if 
a problem arises (continuation 
prescribing)      
xii. Prescribing a medicine for a 
patient after the general practitioner 
has made the diagnosis, decided on 
the category of medicine required 
and given the pharmacist relevant 
clinical details (partnership 
prescribing)     
xii. Participating in health promotion 
programmes in the community 
(diabetes screening, run stop 
smoking clinics, weight reduction 
programmes)     
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 Table 2: Total sum of scores of 4-point Likert scale response options for thirteen-
item scale on professional roles of community pharmacists 
 
 4.7.2.4  General practitioners’ attitudes towards collaboration with 
community pharmacists 
This section consisted of six items measuring general practitioners‟ attitudes towards 
collaboration with community pharmacists using 4-point Likert scale response 
options ranging from 1-for “Strongly Disagree” to 4-for “Strongly Agree”, to 
measure the levels of agreement to these items (Table 3). Items in this section were 
constructed from existing similar instruments that measured the willingness of 
general practitioners to collaborate with community pharmacists (Zillich et al., 
2006; Pojskic et al., 2009). They were also structured to reflect the different stages 
of the CWR model as described by McDonough and Doucette, (2001). The variable, 
“general practitioners‟ attitudes towards collaboration with community pharmacists” 
was computed from the total sum of scores of the Likert scale and depicted as: 1) 
Positive Attitudes, and 2) Negative Attitudes, in accordance with the Likert scale 
response options. “Strongly Agree” and “Agree” were summarized as “Positive 
Attitudes” while “Strongly Disagree” and “Disagree” were summarized as 
“Negative Attitudes”. To highlight the depth of positivity, positive attitudes were 
further described as “Highly Positive Attitudes” and “Slightly Positive Attitudes”. 
Likert scale response options were assigned these additional labels to better qualify 
the variable as seen in Table 4. “Strongly Agree” Likert scale responses option 
corresponds to “Highly Positive Attitudes”, “Agree” Likert scale responses option 
Likert scale response options Scores of 
Likert scale 
response 
options 
Maximum 
obtainable 
scores 
Limits of 
scores 
Strongly Agree (good perceptions) 4 52 40-52 
Agree (fair perceptions) 3 39 27-39 
Disagree    (poor perceptions) 2 26 14-26 
Strongly Disagree (poor perceptions) 1 13 0-13 
 
 
 
 
43 
 
corresponds to “Slightly Positive Attitudes”. “Strongly Disagree” and “Disagree” 
Likert scale response options correspond to “Negative Attitudes”. 
To determine the stage of collaboration where general practitioners have the most 
positive attitudes, items in the scale were structured to fit the different stages of the 
CWR model (Section 4.7.2.1). Table 5 shows the grouping of the items in the scale 
into the different stages of collaboration. The total sum of scores for items in each 
stage of collaboration was computed and the median calculated. For stage 0, the 
total sum of scores was averaged to even out the scores in each stage of 
collaboration. The median was then calculated. The stage of collaboration with the 
highest median is taken as the stage where general practitioners have the most 
positive attitudes.  
 
Table 3: Six-item scale on general practitioners‟ attitudes toward collaboration with 
community pharmacists 
Collaboration 
Strongly  
Agree Agree Disagree 
Strongly  
Disagree 
i. Community pharmacists  
should contact me for issues 
with my  prescription during the 
dispensing process     
 ii. Community pharmacists 
should alert me of possible 
adverse drug reaction     
 iii. Community pharmacists can 
call me referrals for services 
they have specially trained for 
(e.g. anticoagulation service.)     
 iv. I would accept drug  
information      (dosage, drug 
interaction) from community     
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Table 4: Total sum of scores of 4-point Likert scale response options for six-item 
scale on general practitioners‟ attitudes towards collaboration with community 
pharmacists 
 
 
 
 
 
pharmacists  
v. I would give patients‟ clinical 
information to community 
pharmacists  to assist in making 
judgments     
vi. formalized arrangements for 
exchange of information 
between community pharmacists  
and general practitioners is vital 
to patient care     
Likert scale response options Scores for 
Likert scale 
response 
options 
 
Maximum 
obtainable 
scores 
Limit 
of 
scores 
“StronglyAgree”                                 
(highly positive attitudes) 
4 24 19-24 
Agree (Slightly positive attitudes) 3 18 13-18 
Disagree (negative attitudes) 2 12 7-12 
Strongly Disagree (negative attitudes) 1 6 0-6 
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Table 5: Grouping of items on general practitioners‟ attitudes toward collaboration 
with community pharmacists‟ scale into the different stages of collaboration of the 
CWR model 
 
 
 
 
 
4.7.2.5  Current collaboration between general practitioners and community 
pharmacists 
This section was used to determine current collaborative practices between general 
practitioners and community pharmacists in the Cape Metropolis. Eight items 
measured the frequency of interaction using a range of scores from 1- for “never” to 
5-for “more than 5 times” in 6 months (table 6). Some items in this section were 
constructed from an existing similar instrument that measured the frequency of 
interactions between general practitioners and community pharmacists (Pojskic et 
al., 2009). The items were also structured to reflect the different stages of the CWR 
model as described by McDonough and Doucette, (2001). The variable, “current 
collaboration between general practitioners and community pharmacists” was 
computed from the total sum of scores of the Likert scale and depicted in 4 ways to 
better describe the variable as: 1) High-level collaboration; 2) Mid-level 
collaboration; 3) Low-level collaboration; 4) No collaboration. Likert scale response 
options were assigned these additional labels as seen in Table 7. Frequency of 
collaborations greater than “5 times” was equivalent to “High-level collaboration”; 
Frequency of collaboration between “4-5 times” was equivalent to “Mid-level 
collaboration”; Frequency of collaboration between “1-3 times” was equivalent to 
“Low-level collaboration”; “No collaboration” was equivalent to response option 
“Never”. 
Stage of collaboration Items  
Stage 0 collaboration Questions i, ii, iv 
Stage 1 collaboration Question iii 
Stage 3 collaboration Question v 
Stage 4 collaboration Question vi 
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To determine the stage of collaboration where most of the current collaboration 
between general practitioners and community pharmacists occur, items in the scale 
were structured to fit the different stages of the CWR model (section 4.7.2.1). Table 
8 shows the grouping of items into the different stages of collaboration. The total 
sum of scores for items in each stage of collaboration was computed and the median 
calculated. For stage 0 and stage 4, the total sums of scores were averaged to even 
out the scores in each stage of collaboration. The medians were then calculated. The 
stage of collaboration with the highest median is taken as the stage where most of 
the current collaboration between general practitioners and community pharmacists 
occurs.  
Table 6: Eight-item scale on current collaboration between general practitioners and 
community pharmacists within the past 6 months  
Collaboration 
More  
than 5 
times  
4-5  
times 
2-3  
times  Once  Never  
Median  
Likert 
i. A community 
pharmacist contacted 
me because of issues 
with my prescription 
during the dispensing 
process (dosage errors, 
contra-indications)       
ii. A community 
pharmacist  alerted me 
of possible adverse drug 
reactions to prescribed 
medication       
iii. A community 
pharmacist  
visited/called me to 
request for patient 
referral for services       
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beside  dispensing  for 
which he has specially 
trained (anticoagulation 
service) 
iv. I referred my patient 
to a community 
pharmacist for the  
above       
v. A community 
pharmacist provided me 
with drug information 
on asking (dosage, drug 
interaction)        
 vi. I provided my 
patients‟ clinical  
information to a 
community pharmacist 
for him to make better 
therapeutic judgments       
 vii. A community 
pharmacist  and I have 
developed a formalized 
arrangement for 
exchange of information 
and provision of 
services       
viii. How many times 
has such collaboration 
improved patients‟ 
health outcomes?        
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Table 7: Total sum of scores of 5-point Likert scale response options for eight-item 
scale on current collaboration between general practitioners and community 
pharmacists within the past 6 months                                                            
 
 
 
 
 
 
Likert scale response options 
and variable qualifiers 
Scores for 
Likert scale 
response  
options 
 
Maximum 
obtainable 
scores 
Limits of 
scores 
> 5 times (high-level 
collaboration) 
5 40 33-40 
4-5 times (mid-level 
collaboration) 
4 32 25-32 
1-3 times (Low-level 
collaboration) 
2 and 3 16 and 24 9-24 
Never (no collaboration) 1 8 0-8 
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Table 8: Grouping of items on the current collaboration between general 
practitioners and community pharmacists‟ scale into the different stages of 
collaboration of the CWR model  
 
 
 
 
 
 
4.7.2.6  Barriers to collaboration between general practitioners and community 
pharmacists 
This section consists of a 15 items scale which used 4-point Likert scale response 
options ranging from 1-for “Strongly Disagree” to 4-for “Strongly Agree” to 
measure barriers to general practitioners‟ inter-professional collaboration with 
community pharmacists. Items in this section were selected from studies on barriers 
to collaboration between general practitioners and community pharmacists and 
literature on the same topic (Hughes & McCann, 2003; Dobson et al., 2006; Bryant 
et al., 2009; Pojskic et al., 2009). Descriptive item-analysis was done using 
frequencies and percentages and only statements confirmed as barriers would be 
considered for discussion. 
4.7.2.7  Prospects of enhanced future collaboration between general 
practitioners and community   pharmacists                                                                                                                                                                               
This section also served as the desired collaboration model to establish the kind of 
collaboration desired between general practitioners and community pharmacists. It 
consisted of 6 items which used 4-point Likert scale response options ranging from 
1-for “Strongly Disagree” to 4-for “Strongly Agree” to measure the levels of 
agreement to these items (table 9). The items in this section were structured to 
Stages of collaboration Items  
Stage 0 collaboration Questions i, ii, v 
Stage 1 collaboration Question iii 
Stage 2 collaboration Question iv 
Stage 3 collaboration Question vi 
Stage 4 collaboration Question vii, viii 
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reflect the different stages of the CWR model as described by McDonough and 
Doucette, (2001) and were used to measure the willingness of general practitioners 
to have enhanced future collaboration with community pharmacists at the different 
stages. The variable “prospects of enhanced future collaboration between general 
practitioners and community pharmacists” was computed from the total sum of 
scores of the Likert scale and depicted in two ways to better describe the variable as 
shown in table 10 as:  
1) Good prospects of enhanced future collaboration, 
2) Poor prospects of enhanced future collaboration.  
Likert scale response options were collapsed and assigned these additional labels. 
“Strongly agree” and “Agree” Likert scale response options were collapsed and 
summarised as “Good prospects of enhanced future collaboration”. “Disagree” and 
“Strongly Disagree” Likert scale response options were collapsed and summarised 
as “Poor prospects of enhanced future collaboration”. 
To determine the stage of collaboration where general practitioners have the highest 
prospects of enhanced future collaboration, items in the scale were structured to fit 
the different stages of the CWR model (section 4.7.2.1). Table 11 shows the 
grouping of items into the different stages of collaboration. The total sum of scores 
for items in each stage of collaboration was computed and the median calculated. 
For stage 0, the total sum of scores was averaged to even out the scores in each stage 
of collaboration. The median was then calculated. The stage of collaboration with 
the highest median is taken as the stage where general practitioners have the best 
prospects of enhanced future collaboration. 
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Table 9:  Six-item scale on prospects of enhanced future collaboration between 
general practitioners and community pharmacists 
 
 
 
Collaboration 
Strongly 
Agree Agree Disagree 
Strongly 
Disagree 
i. Collaborative care or co-
management of patients (especially 
chronically ill Patients).      
ii.  Exchange of patient information 
for  better clinical and therapeutic  
judgments     
iii. Referral of patients to  
community pharmacists  for other 
specialized services (e.g. 
anticoagulation service)      
iv. Health promotion programmes 
(e.g. smoking cessation, weight 
loss etc)       
v. Exchange of information as a 
result of patients‟ negative reaction 
to prescribed medication     
vi. Exchange of information on 
prescription issues such as safety 
and therapeutic duplications     
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Table 10: Total sum of scores of 5-point Likert scale response options for six-item 
scale on prospects of enhanced future collaboration between general practitioners 
and community pharmacists 
 
Likert scale response options 
Scores for 
Likert scale 
response 
options 
Maximum 
obtainable 
scores 
Limit of 
scores 
Strongly Agree and Agree             
(Good prospects of collaboration) 4 and 3 24 13-24 
Disagree and Strongly Disagree      
(Poor prospects of collaboration) 2 and 1 12 0-12 
 
 
 
Table 11: Grouping of items on the prospects of enhanced future collaboration 
between general practitioners and community pharmacists‟ scale into the different 
stages of collaboration of the CWR model  
 
 
 
 
 
Stage of collaboration Items  
Stage 0 collaboration Questions v, vi 
Stage 1 collaboration Question iv 
Stage 2 collaboration Question iii 
Stage 3 collaboration Question ii 
Stage 4 collaboration Question i 
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4.7.3 PRETESTING AND RELIABILITY OF THE INSTRUMENT 
4.7.3.1 Pre-testing 
The questionnaires were pre-tested among a convenient sample group of five 
general practitioners representative of the target population who did not form part of 
the main survey. The following information was obtained: 
a) Clarity of questions 
b) Length of the questionnaire 
c) Time required to complete the questionnaire 
d) Method of administering the questionnaire 
e) Comments or suggestions regarding general practitioners‟ incentives 
During the pilot phase, the time that was required to complete the questionnaire was 
established to be between 10 and 15 minutes. One of the recommendations that 
emerged from the pre-test was that the researcher should note any contributions or 
comments made by the study participants outside the options provided and as such 
open-ended questions were included in the barriers to collaboration and prospects of 
enhanced future collaboration sections. The participants were also encouraged to 
write any other comments that they could beside each question. It was also obvious 
that to be able to book appointments with the general practitioners in order to have 
their full attention and collect the completed questionnaire in one visit, a 
consultation fee needed to be paid. The frequency of occurrence of collaboration 
between general practitioners and community pharmacists was measured within 6 
months time limit in this study. A similar study measured occurrence of 
collaboration in one week but data gathered from the pilot phase indicated that 
measuring the frequency of collaboration between general practitioners and 
community pharmacists for less than 6 months would not yield useable data. 
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4.7.3.2  Reliability 
The reliability of the scales in the instrument used in the study was measured by 
assessing the internal consistency of the items that made up each scale. Because the 
items in each scale of the instrument were selected or structured from different 
sources, making it a somewhat new instrument, there were no pre-existing measures 
of reliability with which to compare. This also made the need for a reliability test 
more important. However, due to funding and time constraints, the pilot study did 
not include enough participants to be used for a reliability test. Therefore, reliability 
was calculated using data from the main study. Internal consistency describes the 
degree to which the items included in a scale can measure the intended construct 
consistently over time. This indicator of a scale‟s reliability was used instead of the 
test-retest indicator because it is not subjective to the moods and emotions of 
participants. The internal consistency of the items making up the scales in the study 
was assessed using Cronbach‟s alpha coefficient which is one of the most commonly 
used methods of assessing internal consistency in medical and behavioural sciences.  
Also, it provides an indication of the average correlation among all of the items that 
make up the scale (Pallant, 2005:6).The minimum Cronbach‟s alpha coefficient 
recommended for a reliable scale is 0.70 (Negahban et al., 2011). A negatively 
worded item in the barriers to collaboration between general practitioners and 
community pharmacists‟ scale was reversed prior to the determination of the 
Cronbach‟s alpha coefficient. This scale was also only intended for descriptive item 
analysis; therefore it was excluded from further statistical analyses. The relationship 
of individual items to the overall reliability of the scale was measured using the 
alpha if item is deleted measurement. The Cronbach‟s alpha reliability coefficients 
for internal consistency of each scale are presented as tables in the next chapter. 
 
4.7.3.3  Strategies to minimize random and systematic errors 
Data was initially entered into Epi Info (version 3.5.1., 2008) because it has the 
features that can avoid data entry errors and then exported to IBM SPSS Statistical 
software for analysis (version19, 2010). The questionnaires were kept as short as 
possible to reduce incomplete responses. Though it was self-administered, the 
researcher was present to answer any questions from the study participants and also 
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to note any other suggestions or comments for qualitative analysis. The survey was 
conducted by one researcher. 
4.8 RESEARCH VARIABLES 
There were a total of ten variables from the questionnaire. They included five of the 
demographic characteristics of the participants with the exception of the location of 
practice of study participants and the other five constructs measured by scales in the 
questionnaire. The other five variables which were not in the questionnaire were 
represented in the different stages of collaboration as described by McDonough and 
Doucette, (2001). 
 
4.8.1 VARIABLES IN THE QUESTIONNAIRE 
They include five demographic characteristics of participants and five constructs 
measured by scales in the questionnaire 
1. Age of general practitioners 
2. Gender of general practitioners 
3. Years in practice 
4. Nature of practice 
5. Number of patients seen per day  
6. General practitioners‟ perceptions of the professional roles of community 
pharmacists 
7. General practitioners‟ attitudes to collaboration with community pharmacists 
8. Current collaboration between general practitioners and community 
pharmacists 
9. Barriers to collaboration between general practitioners and community 
pharmacists 
10. Prospects of enhanced future collaboration between General practitioners 
and community pharmacists 
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4.8.2 VARIABLES NOT IN THE QUESTIONNAIRE 
These variables represent the different stages of collaboration according to the CWR 
model used for structuring questions on collaboration. 
1. Stage 0 collaboration 
2. Stage 1 collaboration 
3. Stage 2 collaboration 
4. Stage 3 collaboration 
5. Stage 4 collaboration 
 
4.8.3 CLASSIFICATION OF VARIABLES       
This section presents variables that fall into the two classifications of variables 
usually used in research. The two classes are: 
a) Predictor or independent variables 
b) Outcome or dependent variables 
 
4.8.3.1 Predictor or independent variables 
These are variables that are being manipulated in a research study in order to 
observe the effect on a dependent or outcome variable 
4.8.3.1.1 Main predictor variable 
General practitioners‟ perceptions of the professional roles of community 
pharmacists in patient care 
4.8.3.1.2 Other predictor variables from the questionnaire 
1. Age of general practitioners 
2. Gender of general practitioners 
3. Years in practice 
4. Nature of practice 
5. Number of patients seen per day  
6. General practitioners‟ attitudes to collaboration with community pharmacists 
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4.8.3.2 Outcome or dependent variables 
The outcome or dependent variable is dependent on the independent variable or is 
the outcome of the manipulations on the independent or predictor variable.  
 
4.8.3.2.1 Main outcome variable 
The main outcome variable is the desired collaboration between general 
practitioners and community pharmacists (prospects of enhanced future 
collaboration). 
4.8.3.2.2 Other outcome variable 
The other outcome variable being looked at is the current collaboration between 
general practitioners and community pharmacists.  
The various possible associations between these variables are expressed in the null 
and alternative hypotheses.  
4.9 STATISTICAL ISSUES 
This section presents statistical issues such as hypotheses, sample size and power, 
and data analysis. 
4.9.1 HYPOTHESES 
Null and alternative hypotheses generated from the research questions are presented 
below. 
4.9.1.1 Null hypothesis 
There is no correlation between general practitioners‟ perceptions of the professional 
roles of community pharmacists in patient care and the desired collaboration 
(prospects of enhanced future collaboration) between general practitioners and 
community pharmacists. 
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4.9.1.2 Alternative hypothesis (2-tailed) 
There is a direct correlation between general practitioners‟ perceptions of the 
professional roles of community pharmacists in patient care and the desired 
collaboration (prospects of enhanced future collaboration) between general 
practitioners and community pharmacists. The alternative hypothesis is two-tailed 
because the prediction between the predictor and outcome variables does not specify 
a direction of increase or decrease (Trochim, 2006). 
4.9.2 SAMPLE SIZE AND POWER  
The sample size calculation was based on the alternative hypothesis. The correlation 
coefficient (r) was used to calculate the sample size using the main predictor and 
outcome variables since they are continuous, also because the linear association 
between the two variables can be measured (Hulley et al., 2007). 
Sample size, N was calculated using the following procedure  
a) The null hypothesis was stated and it was decided that the alternative hypothesis 
was two-tailed as stated earlier 
b) The effect size (r) which is the absolute value of the smallest correlation 
coefficient (r) that would possibly be detected is 0.5 
c)  Alpha (α, 2- tailed) was set at 0.05 
d)  Beta (β) at 0.1(90% power) 
    C = 0.5 * In [(1+r) / (1-r)] 
zα= the standard normal deviate for α 
zβ= the standard normal deviate for β 
  N = Total number of subjects required (Sample size) 
  N = [(zα + zβ) ÷ C]
2
+ 3 
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Therefore, Sample size, N = 52 (Hulley et al., 1988: 218). 
This would afford a 90% power to detect an association between the main predictor 
and outcome variables. To achieve the calculated sample size, 150 general 
practitioners were randomly selected because of non-responses, inaccurate 
addresses, and unreachable participants.  
4.9.3 DATA ANALYSIS  
Data was entered into a database created on Epi Info (version 3.5.1., 2008) and 
analyzed using IBM SPSS statistical software (version 19, 2010).The pattern of 
association between continuous variables was first established using a scatter plot 
and linearity was confirmed. Shapiro-Wilks test was used to confirm the normality 
hypothesis. Some data was found not to be normally distributed and as such non-
parametric tests were used for analysis as parametric tests require all data to be 
normally distributed. Also, Likert responses can be analyzed using non-parametric 
tests when treated as ordinal data as is done in the study. This also informs the use of 
medians as measures of central tendency. In addition, medians are less influenced by 
extreme values than means. 
4.9.3.1 Univariate descriptive analysis 
Frequencies and percentages were used for describing categorical variables while 
continuous variables were analyzed with medians and ranges. For convenience, each 
section was summarized into a single table. Thematic diagrams of the open-ended 
questions are presented with the comments made by general practitioners. 
Comments were found to fit the three characteristics that affect the development of a 
CWR as proposed by McDonough and Doucette, (2001) and analyzed accordingly 
as participant, context and exchange characteristics.   
4.9.3.2 Inferential analyses 
This section presents the statistical tests that would be used for analysis. Inferential 
analyses are used to infer relationships between or among variables and also from a 
study sample to the population. Only bivariate analyses were carried out in this 
study. 
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4.9.3.2.1 Bivariate analysis 
The relationship between variables is determined using bivariate analysis. First, 
Spearman‟s Rank Order correlation was used to explore associations between 
continuous variables. The value [rho (r) value] of the strength of the correlation 
(strength of the relationship) between variables would be interpreted using the 
guidelines suggested by Cohen (1988), as presented in table 12 below. Secondly, 
other bivariate analysis were carried out using graphical explorations of associations 
between participants‟ demographic characteristics and continuous variables were 
carried out, then additional non-parametric techniques used to compare categorical 
and continuous variables such as Mann-Whitney U Test and Kruskal-Wallis Test 
which were carried out to confirm the statistical significance of the results of the 
graphical explorations. 
 
Table 12: Cohen‟ guideline for interpreting the strength of correlation between 
variables 
 
 
 
 
4.10 ETHICAL CONSIDERATION 
Ethical approval for this project was obtained from the University of the Western 
Cape, Senate Ethics Committee (Ethical Clearance Number: 10/4/29). 
Confidentiality and anonymity was maintained at all times since the names of the 
participants were never linked with the questionnaires. The participants were 
assigned a unique study number that was used on the questionnaires. Personally 
identifying information was retained separately from other study data. 
Dissemination of findings would also not contain any personally identifying 
information. All participants were issued with consent forms to sign before 
rho (r) value  Size of correlation 
±0.10- 0.29  small correlation 
±0.30- 0.49 medium correlation 
±0.50- 1.0 large correlation 
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completing the questionnaires. Data was entered into a research database and was 
identified only using the study number. Participants were free to leave any questions 
unanswered and could withdraw from the study at any stage. 
4.11 LIMITATIONS OF THE STUDY 
A major limitation experienced in the course of carrying out the study was the 
inaccurate addresses and phone numbers of some general practitioners contained on 
the list obtained from the South African Medical Association which was used for 
stratifying participants into the 8 suburban areas of the Cape Metropole. This led to 
a third of the randomly selected sample being inaccessible despite them fulfilling the 
eligibility criteria (50 out of 150).  Of the 100 accessible participants, 25 rejected the 
invitation to participate in the survey for reasons such as time constraints and 
disinterest in the study topic. This group of general practitioners may have 
introduced a contrasting perspective to the study. Irrespective of this problem, the 
sample was still very well distributed within the Cape Town Metropolis, covering 41 
areas, spread within 7 of the 8 suburban areas.  
A larger number of general practitioners could have also been recruited if more 
funds and researchers were included in the study since the study design required a 
lot of travelling which was tiring for one researcher. This would have increased the 
generalisability of the study.  
Generalizing the study findings could be compromised as only general practitioners 
who were members of SAMA were included in the study. SAMA membership is 
voluntary and might not be a true reflection of the population of general 
practitioners in the Cape Metropole unlike membership of the HPCSA. Also 
generalizing the study findings could be compromised since the study was limited to 
the Cape Metropole area alone which can be described as an urban area and the 
experiences of general practitioners in rural areas were not considered.  
Another limitation is that the study measured cross-sectional data because data was 
collected once from a single sample. Therefore, there is limited information on 
changes that might take place over time. A longitudinal study would be needed to 
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track changes that occur in inter-professional collaboration between general 
practitioners and community pharmacists.  
The introduction of consultation fees could have introduced positive or negative 
biases into the study which would affect the generalisability of the study.  
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CHAPTER FIVE 
RESULTS 
5.1         INTRODUCTION 
This chapter presents the results of statistical analysis comprising descriptive and 
inferential analyses as described in chapter four. Firstly, all univariate descriptive 
statistics results are presented as quantitative data which are summarized in texts, 
tables and figures as percentages, frequencies, and medians and the qualitative data 
are presented as thematic diagrams being supported by direct quotes from the study 
participants. Secondly, inferential statistical results are presented according to the 
sequence of analysis. Results of associations between continuous variables, obtained 
using Spearman‟s Rank Order Correlation, are presented. Graphical explorations of 
association between categorical and continuous variables and the results of Mann-
Whitney U Test and Kruskal-Wallis Test are used to confirm the statistical 
significance of the graphs. Thirdly, the results of reliability of scales used in the 
instrument and data normality are presented. This chapter ends with a brief summary 
of the main findings.       
5.2         UNIVARIATE DESCRIPTIVE ANALYSIS 
Results of the univariate analyses carried out using frequencies, percentages, and 
medians are presented in this section. 
5.2.1     RESPONSE RATE 
 150 general practitioners were randomly selected to participate in the study. 65 of 
them were inaccessible for various reasons despite fulfilling the eligibility criteria 
(50 were unreachable on phone, one of them passed away, three retired, another 
three migrated, while eight were no longer practicing as general practitioners). Of 
the 85 remaining, 25 declined to participate for reasons such as time constraints and 
disinterest, therefore, leaving only a total of 60 participants. The sixty general 
practitioners consented to participate and completed the study resulting in a final 
usable response rate of 70.6%.  
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5.2.2   QUANTITATIVE DATA 
Demographic data of the study participants and the results of fives scales of the 
instrument constructed with closed and open ended items using Likert scale 
response options are presented here. 
5.2.2.1    Demographics of study participants 
The result of the demographics of study participants is presented in Table 13. The 
result shows that 70% of the participants were males. Most of the participants were 
between the age range of 31 to 40 years and 41 to 50 years, represented at 28.3% 
each; only 3.3% were between 25 to 30 years while older general practitioners            
(above 60 years) were well represented at 23.3%.  Twenty-eight ( 46.7%)  of the 60 
general practitioners  had spent over 20 years in practice, 38.3% spent between 10 to 
20 years in practice and the remaining 15% were in practice for less than 10 years. 
The ratio of dispensing to non- dispensing general practitioners was close at 46.7% 
to 53.3%, respectively, while only 21.7% of the participants saw more than 30 
patients a day.  
5.2.2.2   General practitioners’ perceptions of professional roles of community 
pharmacists 
The results of a 13-item scale measuring general practitioners‟ perceptions of 
professional roles of community pharmacists in healthcare delivery using 4-point 
Likert scale response options scored from 1-for “Strongly Disagree” to 4-for 
“Strongly Agree‟‟ are presented here. The results are presented in table 14. 
The results show that high percentages of general practitioners strongly agreed to 
community pharmacists carrying out the following roles: dispensing prescribed 
medicines (68.3%), providing information to patients on prescribed medicines 
(73.3%), checking prescriptions for indication, safety, and therapeutic indications 
(68.3%), and reporting adverse reactions to drugs to prescribers and health 
authorities (60%). General practitioners expressed less agreement to roles such as: 
monitoring blood pressure and glucose level (46.7%), offering clinical advice to 
general practitioners (42.4%), and offering clinical medicines information to general 
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practitioners (56.7%). Similarly, only 38.3% of general practitioners agreed to 
community pharmacists making dose adjustments according to agreed protocols. On 
the disagreement scale, 55.9% of general practitioners disagreed with community 
pharmacists undertaking a clinically advanced role like partnership prescribing, 
outweighing those who had agreed (43.9%). General practitioners (51.7%) strongly 
agreed at the same percentage to community pharmacists carrying out advanced 
professional roles such as supervising repeat prescriptions for up to 6 months and 
participating in health promotion programmes. 
The median of the total sum of scores for general practitioners‟ perceptions of 
professional roles of community pharmacists was computed to be 42 with the 
median of the Likert scale scores being 4. From table 15, these medians can be 
observed to fall within “good perceptions” range. It can be concluded that general 
practitioners in this study have good perceptions of the professional roles of 
community pharmacists. 
5.2.2.3 General practitioners’ attitudes towards collaboration with community 
pharmacists 
The results of a 6-item scale measuring general practitioners‟ attitudes towards inter-
professional collaboration with community pharmacists in healthcare delivery to 
enhance patients‟ health outcomes using a 4-point Likert scale scored from 1-for 
Strongly Disagree to 4-for “Strongly Agree” are presented here. The variable 
“general practitioners‟ attitudes towards inter-professional collaboration with 
community pharmacists” is depicted in two ways to better describe the variable as: 
1) Positive attitudes, and  
2) Negative attitudes.  
The positive attitudes are further described as either: 
 1) Highly positive attitudes or  
2) Slightly positive attitudes.  
 
 
 
 
 
66 
 
Table 13: Demographics of study participants (N=60) 
 
Participants Frequency (n) Percentage (%) 
Gender   
Male 42 70.0 
Female 18 30.0 
   
Age (years)   
25-30 2 3.3 
31-40 17 28.3 
41-50 17 28.3 
51-60 10 16.7 
More than 60 14 23.3 
   
Years in practice   
Less than 10 years 9 15.0 
10-20 years 23 38.3 
More than 20 years 28 46.7 
   
Nature of practice   
Dispensing doctor 28 46.7 
Non-dispensing doctor 32 53.3 
   
Number of patients seen per day   
Less than 10 4 6.7 
10-20 21 35.0 
21-30 22 36.7 
More than 30 13 21.7 
NB: Percentages do not always total 100% because of rounding to 1 decimal point 
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Table 14: General practitioners‟ perceptions of the professional roles of community 
pharmacists. 
 
Professional roles of 
community pharmacists 
Strongly 
Agree Agree Disagree 
Strongly   
Disagree 
Median 
Likert 
 N (%) N (%) N (%) N (%)  
1.Dispensing prescribed 
medicines to the public 
 41(68.3) 16(26.7) 1(1.7) 2(3.3) 4 
2.Providing information on 
prescribed drugs 
 44(73.3) 16(26.7) 0(0.0) 0(0.0) 4 
3.Checking prescriptions for 
safety 
 41(68.3) 17(28.3) 1(1.7) 1(1.7) 4 
4.Reporting adverse reactions 
 36(60.0) 23(38.3) 1(1.7) 0(0.0) 4 
5.Advising on cost effectiveness 
 28(46.7 ) 28(46.7) 3(5.0) 1(1.7) 3 
6.Monitoring patients adherence 
with therapy 
 27(45.0) 28(46.7) 4(6.7 ) 1(1.7) 3 
7.Monitoring Blood Pressure, 
blood glucose level, and 
cholesterol level 7(11.7) 32(53.3) 14(23.3) 7(11.7) 3 
8.Source of clinical advice to 
general practitioners 17(28.8) 25(42.4) 16(27.1) 1(1.7) 3 
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9.Source of clinical medicines 
information to general 
practitioners 
 20(33.3) 34(56.7) 5(8.3) 1(1.7) 3 
10.Make dose adjustments using 
protocols established with 
prescriber 11(18.3) 23(38.3) 15(25.0) 11(18.3) 3 
11.Supervise repeat 
prescriptions 
 31(51.7) 23(38.3) 4(6.7) 2(3.3) 4 
12.Partnership prescribing 
a 
 6(10.0) 20(33.9) 19(32.2) 14(23.7) 2 
13.Participate in health 
promotion programs 
 31(51.7) 24(40.0) 2(3.3) 3(5.0) 4 
   N=60 except otherwise stated; 
a,
 means, N<60. Scores of 4-point Likert scale      
response options: 4= “strongly agree” (good perception), 3= Agree (moderate 
perception), 2 = Disagree (poor perceptions), 1= Strongly Disagree (poor 
perceptions) 
NB: Percentages do not always total 100.0% because of rounding to 1 decimal 
point. 
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Table 15: Total sum of scores of 4-point Likert scale response options on general 
practitioners‟ perceptions of the professional roles of community pharmacists‟     
scale   
 
Likert scale response options Scores for 
Likert scale 
response 
options 
Maximum 
obtainable 
scores 
Limits of 
scores 
Strongly Agree(good perceptions) 4 52 40-52 
Agree (fair perceptions) 3 39 27-39 
Disagree (poor perceptions) 2 26 14-26 
Strongly Disagree (poor perceptions) 1  13 0-13 
 
The Likert scale response options were assigned these additional labels.  The results 
for this section are shown in table 16.  
The results show that all general practitioners in the study (100%) had positive 
attitudes to community pharmacists contacting them when there was an issue with 
their prescription, with 80% of them having highly positive attitudes. Similarly, 
among 98.3% of general practitioners with a positive attitude, 70% had highly 
positive attitudes to community pharmacists contacting them when there was a 
possible adverse drug reaction to prescribed medication. Most general practitioners 
(96.7%) would accept drug information from community pharmacists with a higher 
proportion (51.7%) displaying slightly positive attitudes. Of the 83.3% of general 
practitioners who were positive that a formalised arrangement with community 
pharmacists was vital to patient care, 50% had slightly positive attitudes about it, 
while 16.7% did not see the need for formalizing arrangements with community 
pharmacists. More general practitioners (41.7%) had slightly positive attitudes to 
referring patients to community pharmacists for services that they were specially 
trained for besides dispensing (31.7% were highly positive). Out of 61.7% of 
general practitioners who consented to sharing patients‟ clinical information with 
community pharmacists only 16.7% were highly positive about it.  
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The median of the total sum of scores for the variable, “general practitioners‟ 
attitudes toward inter-professional collaboration with community pharmacists”, was 
computed to be 20 with the median of the Likert scale scores being 4. From table 17, 
these medians can be observed to fall within the “positive attitudes” range. Table 18 
shows that the highest median of the stages of collaboration on general practitioners‟ 
attitudes toward collaboration with community pharmacists‟ scale is observed in 
stage 0. It can be concluded that general practitioners in this study have positive 
attitudes to inter-professional collaboration with community pharmacists 
especially at stage 0 collaboration. 
 
Table 16:  General practitioners‟ attitudes toward collaboration with community 
pharmacists. 
Collaboration 
Strongly  
Agree Agree Disagree 
Strongly  
Disagree 
Median 
Likert 
 N (%) N (%) N (%) N (%)  
i. Community pharmacists should 
contact me for issues with my  
prescription during the dispensing 
process 48(80.0) 12(20.0) 0(0.00) 0(0.00) 4 
ii. Community pharmacists 
should alert me of possible 
adverse drug reaction 42(70.0) 17(28.3) 1(1.7) 0(0.00) 4 
ii. Community pharmacists can 
call me referrals for services they 
have specially trained for (e.g. 
anticoagulation service.) 19(31.7) 25(41.7) 12(20.0) 4(6.7) 3 
iv. I would accept drug  
information  (dosage, drug 
interaction) from the community 
pharmacists 27(45.0) 31(51.7) 2(3.3) 0(0.0) 3 
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N=60; Scores of the 4-point Likert scale response options: 4 = strongly agree 
(highly positive attitudes); 3= Agree (less positive attitudes); 2= Disagree (negative 
attitudes); 1= Strongly Disagree (negative attitudes) 
NB: Percentages do not always total 100.0% because of rounding to 1 decimal 
point. 
Table 17: Total sum of scores of 4-point Likert scale response options on general 
practitioners‟ attitudes toward collaboration with community pharmacists‟ scale 
 
Likert scale response options Scores for 
Likert scale 
response 
options 
 
Maximum 
obtainable scores 
Limit of 
scores 
strongly agree (highly positive 
attitudes) 
4 24 19-24 
Agree (slightly positive attitudes) 3 18 13-18 
Disagree (negative attitudes) 2 12 7-12 
Strongly Disagree (negative 
attitudes) 
1 6 0-6 
v. I would give patients‟ clinical 
information to community 
pharmacists to assist in making 
judgments 10(16.7) 27(45.0) 12(20.0) 11(18.3) 3 
vi. Formalized arrangements for 
exchange of information between 
community pharmacists and 
general practitioners is vital to 
patient care 20(33.3) 30(50.0) 6(10.0) 4(6.7) 
 
3 
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Table 18: Medians of the stages of collaboration on general practitioners‟ attitudes 
toward collaboration with community pharmacists‟ scale 
 
Stage of collaboration Items  Median 
Stage 0 collaboration Questions i, ii, iv 3.7 
Stage 1 collaboration Question iii 3.0 
Stage 3 collaboration Question v 3.0 
Stage 4 collaboration Question vi 3.0 
 
5.2.2.4   Current collaboration between general practitioners and community 
pharmacists   
This section presents the results of an 8-item scale measuring current collaboration 
between general practitioners and community pharmacists using a 5-point Likert 
scale scored from 1-for “never” to 5-for “less than 5 times”. The frequency of 
interactions between general practitioners and community pharmacists within 6 
months prior to the study is used to determine current collaboration. The results for 
this section are shown in table 19. 
In the 6 months preceding the study, only 15% of general practitioners were 
contacted more than 5 times by community pharmacists because of prescribing 
errors and 3.3% had 4 to 5 alerts of possible adverse reactions to their prescribed 
medications.  In the preceding 6 months, 5% were approached once by community 
pharmacists for referrals for a new service being provided, while the vast majority of 
general practitioners (95%) had never been contacted for such. Patients were 
referred more than five times to community pharmacists for new services they have 
trained for by 8.3% of general practitioners. Some of the general practitioners 
 
 
 
 
73 
 
(36.7%) had never asked a community pharmacist for drug information while only 
11.7% have asked more than 5 times in 6 months. Patients‟ clinical information has 
never been provided by 75% of general practitioners to a community pharmacist. 
One general practitioner (1.7%) indicated he has done it more than 5 times in 6 
months, two (3.3%) 4 to 5 times while 10% have done it once and another 10%, 2 to 
3 times. Formalized arrangements with community pharmacists for exchange of 
information and provision of services does not exist with 68.3% of general 
practitioners, while 31.7% indicated some form of arrangement. A few general 
practitioners (14.5%) agreed that collaborations with community pharmacists have 
improved patients health outcomes more than 5 times, 31.8% also agreed to this at 
lesser frequencies. Some general practitioners (43.6%) did not agree that 
collaboration makes any difference or they have never collaborated with the 
community pharmacists at all.  
The median of the total sum of scores for the variable, „general practitioners‟ current 
collaboration with community pharmacists was computed to be 13 with the median 
of the Likert scale scores being 2. As shown in table 20, these medians can be 
observed to fall within the “Low-level collaborations” range. Table 21 also shows 
that the highest median score of the stages of collaboration of current collaboration 
between general practitioners and community pharmacists within 6 months‟ is 
observed at stage 0 collaboration. Hence, it can be concluded that general 
practitioners in this study have low-levels of stage 0 collaboration with community 
pharmacists. 
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Table 19: Frequencies and percentages of occurrence of collaboration between 
general practitioners and community pharmacists within 6 months 
Collaboration 
More  
than 5 
times  
4-5  
times 
2-3  
times  Once  Never  
Median  
Likert 
 N (%) N (%) N (%) N (%) N (%)  
i. A community pharmacist 
contacted me because of 
issues with my prescription 
during the dispensing 
process (e.g. dosage errors, 
contra-indications etc.) 9(15.0) 6(10.0) 16(26.7) 13(21.7) 16(26.7) 3 
ii. A community pharmacist 
alerted me of possible 
adverse drug reactions to 
prescribed medication 0(0.0) 2(3.3) 7(11.7) 13(21.7) 38(63.3) 1 
iii. A community pharmacist 
visited/called me to request 
for patient referral for 
services beside  dispensing  
for which he has specially 
trained (e.g. anticoagulation 
service) 0(0.0) 0(0.0) 0(0.0) 3(5.0) 57(95.0) 1 
iv. I referred my patient to a 
community pharmacist for 
the  above 5(8.3) 1(1.7) 5(8.3) 4(6.7) 45(75.0) 1 
v. A community pharmacist 
provided me with drug 
information on asking 
(dosage, drug interaction)  7(11.7) 2(3.3) 20(33.3) 9(15.0) 22(36.7) 2 
vi. I provided my patients‟ 
clinical  Information to a 
community pharmacist for 1(1.7) 2(3.3) 6(10.0) 6(10.0) 45(75.0) 1 
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him to make better 
therapeutic judgments 
vii. A community 
pharmacist and I have 
developed a formalized 
arrangement for exchange 
of information and 
provision of services 4(6.7) 3(5.0) 4(6.7) 8(13.3 ) 41(68.3) 1 
viii. How many times has 
such collaboration improved 
patients‟ health outcomes? a 8(14.5 ) 6(10.9) 4(7.3 ) 13(23.6) 24(43.6) 2 
N=60; 
  a
 means N=55; Scores of the 5-point Likert scale: Never = 1, Once = 2, 2-3 
times = 3, 4-5 times = 4 and Greater than 5 times = 5.  
NB: Percentages do not always total 100.0% because of rounding to 1 decimal point. 
Table 20: Total sum of scores of 5-point Likert scale response options on frequencies 
and percentages of occurrence of collaboration between general practitioners and 
community pharmacists within 6 months‟ scale     
                     
Likert scale response options 
and variable qualifiers 
Scores for 
Likert 
scale 
response 
options 
 
Maximum 
obtainable 
scores 
Limits of 
scores 
> 5 times (high-level 
collaboration) 
5 40 33-40 
4-5 times (mid-level 
collaboration) 
4 32 25-32 
1-3 times (Low-level 
collaboration) 
2 and 3 16 and 24 9-24 
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Never (no collaboration) 1 8 0-8 
 
 
 
Table 21: Medians of the stages of collaboration on frequencies and percentages of 
occurrence of collaboration between general practitioners and community 
pharmacists within 6 months‟ scale                           
 
Stage of collaboration Items  Median 
Stage 0 collaboration Questions i, ii, v 2.0 
Stage 1 collaboration Question iii 1.0 
Stage 2 collaboration Question iv 1.0 
Stage 3 collaboration Question vi 1.0 
Stage 4 collaboration Question vii, viii 1.5 
 
5.2.2.5   Barriers to collaboration between general practitioners and community 
pharmacists 
 This section presents the results of a 15-item scale containing statements with 4-
point Likert scale scored from 1-for “Strongly Disagree” to 4-for “Strongly Agree” 
to measure barriers to general practitioners‟ inter-professional collaboration with 
community pharmacists. Descriptive item-analysis was done using frequencies and 
percentages and only statements confirmed as barriers would be considered for 
discussion. The results are presented on table 22. 
The results show that 75.0% of general practitioners agreed that the lack of funding 
for collaboration is a barrier. The absence of a government policy giving sufficient 
recognition to such collaboration was stated by 57.9% of general practitioners to be 
a barrier. Different levels of agreement were exhibited by 73.4% of general 
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practitioners to the statement that patients might find it unacceptable for their 
medical information to be shared with community pharmacists (26.7% strongly 
agreed and 46.7% agreed). Having sufficient confidence in their clinical knowledge 
was stated by 72.8% of general practitioners to be the reason for not collaborating 
with community pharmacists. The possibility of community pharmacists giving 
biased advice for financial gain was stated by 62.1% to be a barrier. 
5.2.2.6 Prospects of enhanced future collaboration between general 
practitioners and community pharmacists   Pharmacists 
This section presents the results of a 6-item scale measuring the prospects of 
enhanced future collaboration between general practitioners and community 
pharmacists using a 4-point Likert scale scored from 1-for “Strongly Disagree” to 4-
for “Strongly Agree”. The variable, “prospects of enhanced future collaboration 
between general practitioners and community pharmacists” is depicted in two ways 
to better describe the variable as:  
1) Good prospects of enhanced future collaboration,  
2) Poor prospects of enhanced future collaboration.  
Table 22: Barriers to collaboration between general practitioners and community      
pharmacists 
 
Barriers to collaboration 
Strongly 
Agree    Agree  Disagree 
Strongly 
Disagree 
 N (%) N (%) N (%) N (%) 
The funding stream currently does 
not  support community 
pharmacists and general 
practitioners collaborating on  
medication management 8(13.3) 37(61.7) 12(20.0) 3(5.0) 
 Government policy now gives 
sufficient recognition to this 3(5.0) 21(36.8) 28(49.1) 5(8.8) 
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approach of patient care  
Patients may find it unacceptable 
for their medical information to be 
shared with community 
pharmacists 
 
 
    16(26.7) 28(46.7) 15(25.0) 1(1.7) 
 Other than to dispense 
prescriptions, community 
pharmacists are on the periphery of 
the core  healthcare team 3(5.0) 15(25.0) 36(60.0) 6(10.0) 
 A community pharmacists‟ 
knowledge of pharmacology and 
clinical use of medicines is 
inadequate to intervene on the 
patient‟s behalf 
 2(3.3) 9(15.0) 35(58.3) 14(23.3) 
 I have sufficient confidence my 
clinical  knowledge to provide this 
service 
a 
 
12(20.3) 31(52.5) 15(25.4) 1(1.7) 
 The patient may get conflicting 
information regarding medicines 
use 4(6.7) 28(46.7) 26(43.3) 2(3.3) 
This collaboration would not 
improve patients‟ medicine-related 
health outcomes. 2(3.3) 3(5.0) 39(65.0) 16(26.7) 
 I don‟t have the time to discuss 
patient-related medicine issues with 
community pharmacists 
a 
1(1.7) 10(16.9) 32(54.2) 16(27.1) 
There is no CP practice in close 
proximity to my surgery. 4(6.8) 6(10.2) 22(37.3) 27(45.8) 
 I have never been contacted by any 
community pharmacist 
a 
3(5.0) 2(3.3) 29(48.3) 26(43.3) 
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The relationship between 
community pharmacists and 
general practitioners is too 
financially competitive to 
encompass this service 
a
. 
 
 
 
2(3.4) 10(16.9) 32(54.2) 15(25.4) 
Community pharmacists can give 
biased advice on the use of 
medicines due to commercial 
pressure 
a 
3(5.2) 33(56.9) 18(31.0) 4(6.9) 
     N=60;
a
 means N < 60. Percentages do not always total 100.0% because of           
rounding to 1 decimal point. 
 
The Likert scale response options were collapsed and assigned these additional 
labels.  The results for this section are shown in table 23.  
The results show that there are good prospects of enhanced future collaboration with 
more than 50% of participants indicating agreements to: collaborative care or co-
managed care of patients especially the chronically ill, exchange of patient 
information for better clinical and therapeutic judgments, referral of patients for 
services that community pharmacists are specially trained for and health promotion 
programmes. All participants agreed to exchange information as a result of patients‟ 
negative reactions to prescribed medication and prescription issues such as safety 
and therapeutic duplications.  The median of the total sum of scores for the variable, 
“general practitioners prospects of enhanced future collaboration with community 
pharmacists” was computed to be 19 with the median of the Likert scale scores 
being 4. As shown in Table 24, these medians can be observed to fall within the 
“good prospects of collaboration” range. Table 25 also shows that the highest 
median score of the stages of collaboration on prospects of enhanced future 
collaboration between general practitioners and community pharmacists‟ scale                                                                                      
is observed at stage 0 collaboration. Hence, it can be concluded there are good 
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prospects of enhanced future collaborations especially at stage 0 between general 
practitioners and community pharmacists. 
Table 23:  Prospects of enhanced future collaboration between general 
practitioners and community pharmacists 
 
 
Collaboration 
Strongly 
Agree Agree Disagree 
Strongly 
Disagree 
Median 
Likert 
 N (%) N (%) N (%) N (%)  
i. Collaborative care or co-
management of patients 
(especially chronically ill 
patients).  20(33.9) 34(57.6) 3( 5.1) 2(3.4) 3 
ii.  Exchange of patient 
information for  better clinical 
and therapeutic  judgments 10(16.9) 37( 62.7) 8(13.6) 4(6.8) 3 
iii. Referral of patients to 
community pharmacists for 
other specialized services (e.g. 
anticoagulation service)  8(13.3) 33(55.0) 15( 25.0) 4(6.7) 3 
iv. Health promotion 
programmes (e.g. smoking 
cessation, weight loss etc )   
 
29(48.3) 29(48.3) 1(1.7) 1(1.7) 3 
v. Exchange of information as 
a result of patients‟ negative 
reaction to prescribed 
medication 29(48.3) 31(51.7) 0.0 0.0 3 
vi. Exchange of information on 
prescription issues such as 
safety and therapeutic 
duplications 32(53.3) 28(46.7) 0.0 0.0 4 
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N= 58; Scores of the 4-point Likert scale: 4= “strongly agree” (good prospects of 
collaboration), 3= Agree (good prospects of collaboration), 2= Disagree (poor 
prospects of collaboration), 1= Strongly Disagree (poor prospects of collaboration). 
NB: Percentages do not always total 100.0% because of rounding to 1 decimal 
point. 
Table 24: Total sum of scores of 5-point Likert scale response options on prospects 
of enhanced future collaboration between general practitioners and community 
pharmacists‟ scale 
                                                                                   
 
Likert scale response options 
Scores for 
Likert scale 
response 
options  
Maximum 
obtainable  
scores 
Limit of 
scores  
Strongly Agree and Agree           (good  
prospects of collaboration) 
 4 and 3 24 13-24 
Disagree and Strongly Disagree (poor 
prospects of collaboration) 2 and 1 12 0-12 
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Table 25: Medians of the stages of collaboration on prospects of enhanced future 
collaboration between general practitioners and community pharmacists‟ scale                                                                                       
 
Stages of collaboration Items  Median 
Stage 0 collaboration Questions v, vi 3.5 
Stage 1 collaboration Question iv 3.0 
Stage 2 collaboration Question iii 3.0 
Stage 3 collaboration Question ii 3.0 
Stage 4 collaboration Question i 3.0 
   
5.2.3 QUALITATIVE DATA 
This section presents the results of the analysis of responses to the open-ended 
questions asked in the questionnaire (appendix III) in quotes. Thematic diagrams 
emerged from each open ended question and are presented as figure 1 and figure 2. 
Figure1 articulates responses to the question on ways of enhancing collaboration, 
while figure 2 summarises responses to the question on other barriers to 
collaboration.  
Hence, this section is divided into these two sub-sections. Comments made by 
participants on ways of enhancing collaboration are further divided into supportive 
comments and suggestive comments. The suggestive comments were classified as 
pharmacists‟ characteristics, exchange characteristics and context characteristics. 
Comments suggesting other barriers to collaboration were classified according to 
those that bordered on professional practice or health systems.  
5.2.3.1      Ways of enhancing collaboration  
General practitioners made several supportive comments about inter-professional 
collaboration and suggestions on how to enhance collaboration with community 
pharmacists. The thematic diagram contains the supportive comments and 
suggestions.   
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5.2.3.1.1   Supportive comments   
 „We have a good relationship with our local pharmacist‟ 
 „Collaboration would take unnecessary burden off general practitioners‟ 
 „Collaboration would help check patients who shop for prescriptions for 
DDAs (Dangerous Drugs of Addiction) 
5.2.3.1.2   Suggestions   
Suggestive responses obtained from study participants were found to fit the three 
classes of characteristics that affect the development of a collaborative working 
relationship (CWR) by McDonough and Doucette, (2001) and they were classified 
as such. 
 
5.2.3.1.2.1     Pharmacists’ characteristics   
This section comprises responses describing the professional knowledge base and 
skills of community pharmacists. 
 “Community pharmacists need lots of education and a change of attitude‟ 
 „Knowledge of the clinical depth of community pharmacists would make 
combined decisions easier‟ 
 “Community pharmacists need to have more knowledge of the use and 
relevance of blood pressure, glucose and cholesterol tests. 
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Figure 1: Thematic diagram of responses to the open-ended question „ways of 
enhancing collaboration‟ 
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Figure 2: Thematic diagram of responses to the open-ended question „barriers 
to collaboration‟ 
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5.2.3.1.2.2   Context Characteristics 
This section comprises responses describing professionalism in community 
pharmacy practice and pharmaceutical care. 
 „If community pharmacists are not concentrating on being pharmacists but 
shop keepers, they can‟t be given more professional responsibilities‟ 
 „Community pharmacists should improve on their advisory roles, especially 
in the use of medical devices like asthma pumps, insulin pens and glucose 
monitoring‟ 
 „The closest pharmacy to me is miles away‟(Khayelitsha) 
5.2.3.1.2.3   Exchange Characteristics   
These responses describe the nature and extent of exchanges (communication, trust, 
respect) expected between general practitioners and community pharmacists. 
 „There should be 2-way communication; patients should be referred back to 
general practitioners if they need reassessment‟ 
 „Monthly electronic feedback between general practitioners and community 
pharmacists‟ 
 „After blood pressure readings are taken and there is a concern, patients 
should be sent to the GP‟ 
 „General practitioners should stop dispensing‟ 
 „Mutual respect for professional boundaries and knowledge, patient interest 
should be first‟ 
 „Community pharmacists should stop dispensing antibiotics without 
prescriptions and medications to chronically ill patients long after their prescriptions 
have expired, this reinforces the fact that commercial interest outweighs clinical 
knowledge and ethics‟ 
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 „Group discussions amongst community pharmacists, general practitioners, 
dieticians, physiotherapists, would help facilitate health promotion programs in the 
community‟ 
 „General practitioners and community pharmacists should jointly attend 
continuing medical education (CME) lectures‟ 
 
5.2.3.2    Other barriers to collaboration    
General practitioners highlighted other barriers to collaboration that were not 
included in the questionnaire. These were summarised into two groups:  
a) Professional practice 
b) Health systems 
5.2.3.2.1      Professional practice 
This comprises responses that described barriers related to ethical issues and 
professional boundaries. 
 „Some patients especially in sub-economic areas cannot afford pharmacy 
prices due to excessive profiteering‟ 
 „Community pharmacists pass opinions on general practitioners prescriptions 
without knowing the reasons behind such decisions‟ 
 „Community pharmacists use general practitioners practice numbers‟ 
 „Community pharmacists might feel general practitioners would not listen to 
them‟ 
 „Community pharmacists are taking away patients from general practitioners 
with their increased clinical services‟ 
 „Community pharmacists do not have patients medical histories to help them 
in decision making‟ 
 „Community pharmacists make drug substitutions without consulting with 
general practitioners‟. 
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 „Community pharmacists are not trained to make clinical diagnoses and give 
appropriate treatments‟ 
 „Big chain pharmacies have a high turnover of community pharmacists 
which impedes collaboration‟ 
 „Locum general practitioners and community pharmacists make 
collaboration difficult‟ 
5.2.3.2.2    Health Systems    
This comprises responses that describe barriers related to health policy issues and 
insurance. 
 „Health Professionals Council of South Africa‟s ethical rules‟ 
 „Policy on dispensing‟ 
 „Pharmacists lack access to malpractice insurance cover‟ 
 „Community pharmacists should be held responsible for adverse reactions 
caused to the patients from POMs (Prescription only medicines) dispensed without 
prescriptions. 
 
5.3      INFERENTIAL ANALYSES 
This section presents the results of statistical analyses carried out to infer relationship 
between variables. The variables are: general practitioners‟ perception of the 
professional roles of community pharmacist, general practitioners‟ attitudes towards 
collaboration with community pharmacists, current collaboration between general 
practitioners and community pharmacists and prospects of enhanced future 
collaboration between general practitioners and community pharmacists.  Non-
parametric tests were used for analysis and only bivariate analyses were carried out. 
This section is divided into 3 subsections. Firstly, test of hypotheses and other 
correlations using Spearman‟s Rank Order Correlation. Secondly, graphical 
explorations of associations between participants‟ demographic characteristics and 
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continuous variables in the questionnaire were carried out. Thirdly, Mann-Whitney 
U Test and Kruskal-Wallis Test were used to confirm the statistical significance of 
the graphical explorations. 
5.3.1   BIVARIATE ANALYSIS 
5.3.1.1     Test of hypotheses 
The null and alternative hypotheses were tested using Spearman‟s Rank Order 
Correlation (r). The results are presented in table 32. 
5.3.1.1.1Null hypothesis 
There is no correlation between general practitioners‟ perceptions of professional 
roles of community pharmacists in patient care and the desired collaboration 
(prospects of enhanced future collaboration). 
5.3.1.1.2       Alternative hypothesis (2-tailed)  
There is a direct correlation between general practitioners‟ perceptions of the 
professional roles of community pharmacists in patient care and the desired 
collaboration (prospects of enhanced future collaboration). 
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Table 26:   Spearman‟s Rank Order Correlation (r) for calculating the strength of 
relationship between general practitioners‟ perceptions of the professional roles of 
community pharmacists and desired collaboration (prospects of enhanced future 
collaboration). 
 
Variables Rho (r) value Two-tailed 
significance 
General practitioners‟  perceptions of 
professional roles of community 
pharmacists 
1.000 - 
Prospects of enhanced future 
collaboration with community 
pharmacists 
0.630 0.0005 
 Correlation is significant at the 0.05 level (2-tailed). 
 
5.3.1.1.3 Calculating the strength of the associations between two continuous 
variables using Spearman‟s Rank Order Correlation 
The result in table 32 suggests that there is a statistically significant, strong, positive 
correlation between general practitioners’ perceptions of the professional roles of 
community pharmacists that desires collaboration (prospects of enhanced future 
collaboration). [r=0.630, p=0.0005]. The null hypothesis is therefore rejected 
(Cohen, 1988). 
5.3.1.2   Strength of associations amongst other continuous variables using 
Spearman’s Rank Order Correlation 
This section presents the results of the Spearman‟s Rank Order Correlation [rho (r) 
values] indicating the strength of the relationship amongst other continuous 
variables. The results are presented in table 33. 
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Table 27:  Spearman‟s rho (r) correlation amongst other continuous variables. 
 
VARIABLES Rho (r) value  Two-tailed 
significance 
General practitioners perceptions‟ of professional 
roles of community pharmacists 
1.000  - 
General practitioners‟ attitudes toward 
collaboration with  community pharmacists 
0.691  0.0005 
Current collaboration between general 
practitioners and community pharmacists 
0.358  0.008 
General practitioners‟ attitudes  toward 
collaboration with  community pharmacists 
1.000  - 
Current collaboration between general 
practitioners and community pharmacists 
0.361  0.007 
Prospects of enhanced future collaboration  
between general practitioners and community 
pharmacists 
0.728  0.0005 
Current collaboration between general 
practitioners and community pharmacists 
 1.000  - 
Prospects of enhanced future collaboration  
between general practitioners and community 
pharmacists 
0.463  0.0005 
     Correlation is significant at the 0.05 level (2-tailed). 
5.3.1.2.1   Correlation between general practitioners‟ perceptions of professional 
roles of community pharmacists and general practitioners‟ attitudes toward 
collaboration 
The results suggest a statistically significant, strong, positive correlation between 
general practitioners’ perceptions of professional roles of community pharmacists 
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and general practitioner’ attitudes toward collaboration, [r= 0.691, p = 0.0005], 
(Cohen, 1988). 
5.3.1.2.2    Correlation between general practitioners‟ perceptions of professional 
roles of community pharmacists and current collaboration between general 
practitioners and community pharmacists 
The results suggest a statistically significant, medium, positive correlation between 
general practitioners’ perceptions of professional roles of community pharmacists 
and current collaboration between general practitioners and community 
pharmacists, [r= 0.358, p = 0.008], (Cohen, 1988). 
5.5.1.2.3     Correlation between general practitioners‟ attitudes toward collaboration 
and current collaboration between general practitioners and community pharmacists 
The results suggest a statistically significant, medium, positive correlation between 
general practitioners’ attitudes toward collaboration and current collaboration 
between general practitioners and community pharmacists [r= 0.361, p = 0.007], 
(Cohen, 1988). 
5.3.1.2.4     Correlation between general practitioners‟ attitudes toward collaboration 
and prospects of enhanced future collaboration between general practitioners and 
community pharmacists  
The results suggest a statistically significant, strong, positive correlation between 
general practitioners’ attitudes toward collaboration and prospects of enhanced 
future collaboration between general practitioners and community pharmacists [r= 
0.728, p =0.0005], (Cohen, 1988). 
5.3.1.2.5     Correlation between current collaboration between general practitioners 
and community pharmacists and prospects of enhanced future collaboration between 
general practitioners and community pharmacists    
The result suggests a statistically significant, medium, positive correlation between 
current collaboration between general practitioners and community pharmacists 
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and prospects of enhanced future collaboration between general practitioners and 
community pharmacists   [r= 0.463, p = 0.0005], (Cohen, 1988). 
5.3.1.3.  Additional bivariate analysis 
5.3.1.3.1 Graphical exploration of associations between participants‟ 
demographic characteristics and continuous variables.  
Graphical representations of possible associations between participants‟ demographic 
characteristics and continuous variables are presented here. Participants‟ 
demographic characteristics are: age, gender, years in practice, nature of practice, 
and number of patients seen per day. Continuous variables are: general practitioners‟ 
perceptions of professional roles of community pharmacists, general practitioners‟ 
attitudes toward collaboration with community pharmacists, general practitioners 
current collaboration with community pharmacists and future prospects of enhanced 
collaboration between general practitioners and community pharmacists. 
NB: The statistical significance of all graphically observed associations would be 
confirmed using Mann-Whitney U Test and Kruskal-Wallis Test. 
  
5.3.1.3.1.1 Graphical exploration of associations between participants‟ demographic 
characteristic (age) and continuous variables. 
The influence of age on the independent continuous variables is slight across the 
different age groups. General practitioners who are 51 to 60 years old have the 
highest median of total scores for: perceptions of the professional roles of 
community pharmacists, attitude towards collaboration and prospects of enhanced 
future collaboration with community pharmacists. However, this is without a 
corresponding current collaboration. General practitioners within the age range 31 to 
40years have the highest median of total scores for current collaboration. Those 
within the age range of 25 to 30 years had the lowest median of total scores for: 
current collaboration, perceptions of the professional roles of community 
pharmacists and attitude towards collaboration with community pharmacists. 
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General practitioners older than 60 years had the lowest median of total scores for 
prospects of enhanced future collaboration. 
 
Figure 3: Exploring associations between the age of participants and continuous 
variables 
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Figure 4: Exploring associations between participants‟ gender and continuous 
variables 
 
 
5.3.1.3.1.2   Graphical exploration of associations between participants‟ 
demographic characteristic (gender) and continuous variables.  
 The female general practitioners have slightly higher median of total scores than 
males for current collaboration and prospects of enhanced future collaboration. 
Males have slightly higher scores than females for attitudes towards collaboration. 
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No difference was observed in the median of total scores for males and females for 
perceptions of the professional roles of community pharmacists. 
Figure 5: Exploring associations between number of patients seen by participants 
per day and continuous variables 
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5.3.1.3.1.3   Graphical exploration of possible associations between participants’ 
demographic characteristic (number of patients seen per day) and continuous 
variables 
General practitioners who saw more than 30 patients a day had: the highest median 
of total scores for perceptions of the professional roles of community pharmacists, 
attitudes towards collaboration, prospects of enhanced future collaboration and 
current collaboration with community pharmacists. General practitioners who saw 
less than 10 patients a day had similarly high median of total scores for current 
collaboration with community pharmacists. The least median of total scores for 
perceptions of the professional roles of community pharmacists‟ attitudes towards 
collaboration, prospects of enhanced future collaboration and current collaboration 
with community pharmacists was observed for general practitioners who saw 20 to 
30 patients a day. General practitioners who saw 10 to 20 patients a day had the least 
prospects of enhanced future collaboration. 
5.3.1.3.1.4   Graphical exploration of possible associations between participants’ 
demographic characteristic (nature of practice) and continuous variables.  
The graph below shows that non-dispensing general practitioners had higher median 
of total scores than dispensing general practitioners for current collaboration with 
community pharmacists. The perception of professional roles, attitude to 
collaboration and prospects of enhanced future collaboration with community 
pharmacists are not influenced by the nature of practice.  
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Figure 6: Exploring associations between participants‟ nature of practice and 
continuous variables 
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Figure 7: Exploring associations between participants‟ years in practice and 
continuous variables. 
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5.3.1.3.1.5 Graphical exploration of possible associations between participants‟ 
demographic characteristic (years in practice) and continuous variables.  
General practitioners with more than 10 years of practice had the highest median of 
total scores for perceptions of the professional roles of community pharmacists, 
attitude towards collaboration with community pharmacist, current collaboration but 
low median of total scores for prospects of enhanced future collaboration. General 
practitioners with less than 10 years in practice had the highest median of total 
scores for prospects of enhanced future collaboration and low scores for the other 
constructs. 
5.3.1.3.2       Mann-Whitney U Test 
This section presents the results (table 34) that confirm statistically significant 
associations between participants‟ demographic characteristic, their nature of 
practice (with two groups), and the continuous variable, current collaboration. 
Table 28: Mann-Whitney U Test for difference between current collaboration 
and nature of practice 
 
 Difference between current collaboration and nature 
of practice 
Z -3.932 
Two-tailed significance 0.0005 
The results suggest a statistically significant difference (p=0.0005) in the median of 
total scores of dispensing and non-dispensing general practitioners (nature of 
practice) in their current collaboration with community pharmacists  
5.3.1.3.3       Kruskal-Wallis Test 
This section presents the results (table 35) that confirm statistically significant 
associations between participants‟ demographic characteristic, years in practice 
(with three groups), and the continuous variable, attitude to collaboration. 
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Table 29: Kruskal-Wallis Test for difference between general practitioners‟ attitudes 
toward collaboration with community pharmacists and years in practice 
 
 Differences between general practitioners 
attitude to collaboration and years in practice 
Z 6.996 
Two-tailed significance 0.030 
The results suggest a statistically significant difference (p=0.03) in mean scores of 
general practitioners attitude towards collaboration with community pharmacists 
relative to years in practice. 
5.4 RELIABILITY OF SCALES 
The results of the reliability test carried out by using Cronbach‟s alpha coefficient 
test to measure the internal consistency of the items making up the scales in the 
instrument are presented in table 13.  
Table 13 shows that four of the five scales in the instrument had the alpha 
coefficients above 0.70 which is recommended as the minimum acceptable value. 
The scales used in the study can be said to have satisfactory internal consistency and 
are able to measure the intended constructs consistently. The “barriers to 
collaboration between general practitioners and community pharmacists” scale, 
which had an alpha coefficient of 0.69, was intended for the individual item 
descriptive analysis only, in this regard, the scale was exempted from other 
statistical analysis. The Cronbach‟s alpha coefficient of scales used in the study 
cannot be compared with those reported in similar studies because the items on the 
scales were a composite of newly constructed items as well as items selected from 
various tools in the literature. The Cronbach‟s alpha reliability coefficient for 
internal consistency of individual items relative to the scales in the instrument if the 
item is deleted appear from tables 14 - 17 below. 
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Table 30: Cronbach‟s alpha reliability coefficient for the internal consistency of 
scales in the instrument 
 
Constructs to be measured 
Cronbach’s alpha 
coefficient 
1. General practitioners‟ perceptions of the professional 
roles of community pharmacists 
0.82 
2. General practitioners attitude towards collaboration with 
community pharmacists 
0.77 
3. Current collaboration between general practitioners and 
community pharmacists 
0.76 
4. Barriers to collaboration between general practitioners 
and community pharmacists 
0.69 
5. Prospects of enhanced future collaboration between 
general practitioners and community pharmacists  
0.74 
 
Table 31: Cronbach‟s alpha reliability coefficient for internal consistency of 
individual items relative to the scale for general practitioners‟ perceptions of the 
professional roles of community   pharmacists 
 
Professional roles of community pharmacists 
Cronbach's 
Alpha if Item 
Deleted 
i. Dispensing prescribed medicines to the public 0.83 
ii. Providing  information to patients on prescribed 
medicines  
0.82 
iii. Checking patients‟ prescriptions for indications, safety 
and therapeutic duplications 
0.80 
iv. Reporting adverse reactions to drugs to prescribers and 
health authorities 
0.81 
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v. Advising on the cost- effectiveness of medicines for 
disease states 
0.81 
vi. Monitoring patients‟ adherence therapy and ensuring 
their medicine related needs are met 
0.80 
vii. Monitoring blood pressure, blood glucose levels and 
cholesterol levels 
0.81 
viii. Be a source of clinical advice to general practitioners 
such as in the selection of a medicine for a particular 
disease state 
0.80 
ix. Be a source of clinical medicines information to 
general practitioners 
0.80 
x. Make dose adjustments to a patients‟ medicine using 
protocols established with the prescriber 
0.81 
xi. Supervise repeat prescriptions for a patient according 
to agreed protocols, for up to 6 months, contacting the 
general practitioner if a problem arises 
0.81 
xii. Prescribing a medicine for a patient after the general 
practitioner has made the diagnosis, decided on the 
category of medicine required and given the pharmacist 
relevant clinical details  (Partnership prescribing) 
0.81 
xiii. Participate in health promotion programs in the 
community 
0.81 
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Table 32: Cronbach‟s alpha reliability coefficient for internal consistency of 
individual items relative to the scale for general practitioners‟ attitudes toward 
collaboration with community pharmacists 
 
Items Cronbach's Alpha 
if Item Deleted 
i. Community pharmacists should contact me for issues 
with my prescription during the dispensing process  
0.76 
ii. Community pharmacists should alert me of possible 
adverse drug reactions 
0.75 
iii. Community pharmacists can call me for referrals for 
services they have specially trained for  (for example, 
anticoagulation service) 
0.72 
iv. I would accept drug information (dosage and drug 
interactions) from community pharmacists  
0.71 
v. I would give patients‟ clinical information to community 
pharmacists to assist in making judgments‟  
0.72 
vi. A formalized arrangements for exchange of information 
between the community pharmacists and general 
practitioners is vital to patient care 
0.73 
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Table 33: Cronbach‟s alpha reliability coefficient for internal consistency of 
individual items relative to the scale for current collaboration between general 
practitioners and community pharmacists 
 
Items Cronbach's Alpha 
if Item Deleted 
i. A community pharmacists contacted me because of 
issues with my prescription during the dispensing process 
(e.g. dosage errors, contra-indications etc.) 
0.74 
ii. A community pharmacists alerted me of possible 
adverse drug reactions to prescribed medication 
0.71 
iii. A community pharmacists  visited/called me to request 
for patient referral for services beside  dispensing  for 
which he has specially trained (e.g. anticoagulation 
service) 
0.76 
iv. I referred my patient to a community pharmacists  for 
the  above 
0.73 
v. A community pharmacist provided me with drug 
information on asking (dosage, drug interaction)  
0.71 
 vi. I provided my patients‟ clinical  Information to a 
community pharmacists  for him to make better therapeutic 
judgments 
0.76 
 vii. A community pharmacists  and I have developed a 
formalized arrangement for exchange of information and 
provision of services 
0.72 
viii. How many times has such collaboration improved 
patients‟ health outcomes?  
0.69 
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Table 34: Cronbach‟s alpha reliability coefficient for internal consistency of 
individual items relative to the scale for prospects of enhanced future collaboration 
between general practitioners and community pharmacists  
 
Items Cronbach's Alpha 
if Item Deleted 
i. Collaborative care or co-management of patients       
(especially chronically ill patients).  
0.73 
ii.  Exchange of patient information for  better clinical and 
therapeutic  judgments 
0.69 
iii. Referral of patients to community pharmacists for other 
specialized services    (for example, anticoagulation 
service)  
0.71 
iv. Health promotion programmes (for example, smoking 
cessation, weight loss)   
0.68 
v. Exchange of information as a result of patients‟ negative 
reaction to prescribed medication 
0.70 
vi. Exchange of information on prescription issues such as 
safety and therapeutic duplications 
0.69 
 
5.5    TEST OF DATA NORMALITY  
Shapiro-Wilks test was used to confirm the normality of the data because of the small 
sample size used in the study. Table 18 presents the results of the normality tests for 
the four scales that have been used for all statistical analysis. The results show that 
data obtained from the scales that measured attitude to collaboration and current 
collaboration between general practitioners and community pharmacists were not 
normally distributed but the data obtained from the scales that measured general 
practitioners‟ perceptions of the professional roles of community pharmacists and 
prospects of enhanced future collaboration between general practitioners and 
community pharmacists were normally distributed. Non-parametric tests were used 
for analysis as parametric tests require all data to be normally distributed. This also 
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informs the use of medians and ranges as measures of central tendency and 
dispersion respectively. 
Table 35: Test of data normality using Shapiro-Wilks Test 
 
Scales Shapiro-Wilks 
Significance value 
1.General practitioners‟ perceptions of 
the professional roles of community 
pharmacists 
0.087 
2.General practitioners‟ attitudes towards 
collaboration with community 
pharmacists 
0.000 
3.Current collaboration between general 
practitioners and community pharmacists 
0.009 
4.Prospects of enhanced future 
collaboration between general 
practitioners and community pharmacists 
0.067 
 
 
5.6    SUMMARY OF MAIN FINDINGS 
The salient findings in this study are summarised in bullet point form below: 
 A relatively high response rate of 70.6 % was achieved in the study which 
might be attributed to the study design and probably the payment of 
consultation fees to buy participants over. 
 General practitioners have good perceptions of the professional roles of 
community pharmacists but favour traditional roles over advanced roles 
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 General practitioners have positive attitudes towards inter-professional 
collaboration with community pharmacists especially at stage 0. 
 General practitioners have low-levels of collaboration with community 
pharmacists mostly at stage 0. 
 Prospects of enhanced future collaboration are good especially at stage 0. 
 General practitioners‟ perceptions of the professional roles of community 
pharmacists have a direct influence on their attitude towards collaboration 
(r=0.691, p=0.0005) as well as desired collaboration (prospects of enhanced 
future collaboration, r=0.630, p=0.0005). 
 General practitioners‟ current collaboration with community pharmacists is 
not commensurate with the good perceptions of their professional roles 
(r=0.358, p=0.008), positive attitudes towards collaboration (p=0.007) and 
good prospects of enhanced future collaboration observed in the study 
(r=0.463, p=0.0005). 
 Non-dispensing general practitioners have more frequent collaboration with 
community pharmacists than dispensing general practitioners (p=0.0005). 
 General practitioners‟ who had spent more than 10 years in practice had 
more positive attitudes towards collaboration compared with those less than 
10 years in practice (p=0.03). 
 All other demographic characteristics did not have any statistically 
significance on collaboration. 
 General practitioners identified the lack of remuneration for collaboration as 
a barrier. 
 The absence of a government mandate or policy supporting collaboration 
was stated as a barrier. 
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 Inability of general practitioners to share patients‟ information with 
community pharmacists was also stated as a barrier. 
 Some general practitioners stated that they did not need to collaborate with 
community pharmacists. 
 General practitioners stated as a barrier the community pharmacists‟ 
questionable professional ethics particularly over financial gains. 
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CHAPTER SIX 
DISCUSSION 
6.1  INTRODUCTION 
The main findings from the results obtained in this thesis would be discussed in this 
chapter. The discussion would be divided into two sections; firstly the results in the 
quantitative data would be discussed followed by discussion of the responses in the 
qualitative data.  For the quantitative data, the main hypothesis would be central to 
the discussion while other findings of statistical importance would be briefly 
mentioned; the current level and stage of collaboration between general practitioners 
and community pharmacists in patient care would be discussed in the light of the 
results obtained for this thesis. The influence of general practitioners‟ perceptions of 
the professional roles of community pharmacists on desired collaboration, which is 
measured as the prospects of enhanced future collaboration between general 
practitioners and community pharmacists in this thesis, would be explored. The 
likelihood of enhanced future collaborations between general practitioners and 
community pharmacists and the requirements to achieve this would be discussed. 
Possible barriers to the envisioned collaboration would also be explored. In addition, 
the reliability of the scale and the response rate observed in the study are also 
discussed. For the qualitative data, responses to the open-ended questions would be 
discussed under the headings described in the thematic diagram firstly as ways of 
enhancing collaboration and secondly as other barriers to collaboration.  
6.2  QUANTITATIVE DATA 
Discussion of the results of the analysis of quantitative data collected in this thesis is 
presented below in response to the research questions.    
6.2.1 CURRENT LEVEL AND STAGE OF COLLABORATION BETWEEN 
GENERAL PRACTITIONERS AND COMMUNITY PHARMACISTS IN 
PATIENT CARE  
Determination of the current level of collaboration between general practitioners and 
community pharmacists is informed by the past disputes which occurred between 
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dispensing general practitioners in particular and community pharmacists.  
Knowledge of the current level and stage of collaboration would determine 
measures that could be necessary to enhance inter-professional collaboration in the 
future. Results obtained in this study showed that the general practitioners and 
community pharmacists are collaborating at low-levels which means, any 
interactions between the two groups only occurred like three times in six months. 
Most of the interactions that occur are at stage 0 of the CWR model indicating 
interactions of a discrete nature such as dispensing prescriptions that are faxed or 
telephoned to the pharmacy, identifying adverse drug interactions and answering 
drug information questions, all of which are typical of the drug-oriented traditional 
roles of community pharmacists. 
The time interval used to determine the frequency of interactions is particularly 
peculiar to this study as explained in chapter 4 (Section 4.8.3.1). Pojskic et al. 
(2009) measured the frequency of collaboration within one week but the pre-test 
informed the use of 6 months in this study. This result reveals the poor state of inter-
professional collaboration between general practitioners and community 
pharmacists. Invariably, interactions rarely occur. It can be assumed that the 
infrequent interactions between them are because neither of the two professionals 
are ready to invest extra efforts to develop an inter-professional relationship, 
probably due to the unresolved dispute that have always occurred between them. 
The patient is caught in the middle of this controversy and denied the potential 
benefits of collaborative practices. Another reason could be the issue of professional 
hierarchy or dominance. General practitioners might feel that they are at the top of 
the hierarchy of the medical profession and as such they do not need to collaborate 
with community pharmacists. This reason was indicated as one of the barriers to 
inter-professional collaboration by 73% of general practitioners in this study. Some 
general practitioners explained further that their response to the statement was a way 
of defending their professional competence although their appreciation for the role 
of the community pharmacists revealed the ambiguity from the question.     
Collaborations at higher stages of the CWR model could have been hindered 
because general practitioners are not aware of the professional roles and skills of 
community pharmacists. The general practitioners‟ perceptions of the professional 
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roles of community pharmacists and their attitudes towards inter-professional 
collaboration with community pharmacists carried out in this study revealed that 
general practitioners have good impressions of the professional roles of community 
pharmacists but they still favour traditional professional roles above the advanced or 
extended roles. Results from the study also show that general practitioners have 
positive attitudes towards inter-professional collaboration with community 
pharmacists but with preference for collaborative activities at stage 0 of the CWR 
model. Higher perception scores for traditional roles and highly positive attitudes for 
stage 0 activities are reasons for the observed stage of current collaboration.  
This is an indication that general practitioners are more comfortable with 
community pharmacists carrying out their traditionally technical roles which 
emphasizes the drug product more than the more clinically, disease and patient-
oriented roles. The issue of community pharmacists encroaching on the professional 
boundaries of general practitioners might be behind this thinking in view of the 
battle for professional turfs which occurred between the two professions earlier in 
South Africa (Gilbert, 1998).   
General practitioners might also think that community pharmacists lack the 
government‟s mandate to carry out the extended and advanced roles as these are 
evolving roles for community pharmacists. They assume that community pharmacists 
might not be adequately skill to carry out such services as stated in the qualitative data 
that „community pharmacists need lots of education’. General practitioners also seem 
to question the effectiveness of such services in improving patients‟ health outcomes. 
These assumptions might have been responsible for the preference for the simpler, 
less patient-oriented traditional roles.   
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Similar observations were made from the findings in this study in studies carried out 
in New Zealand, USA, Netherlands and India where general practitioners favoured 
the traditional roles carried out by community pharmacists above the extended or 
advanced roles (Bleiker & Lewis, 1998; Bradshaw & Doucette, 1998; Smith et al., 
2002; Muijrers et al., 2003; Adepu & Nagavi., 2006; Bryant et al., 2009). 
Preservation of professional boundaries, mandate to practice, legitimacy, adequate 
skills and effectiveness of extended and enhanced roles to improve the health 
outcomes of patients were the reasons proffered for the observations made in these 
studies. In India, Adepu and Nagavi also noted that although the law states that a 
qualified person is essential to open and run a community pharmacy (Malik, 1984), 
35% of pharmacies are run by non-pharmacists who rent the certificates of qualified 
pharmacists. This influences the contributions such persons acting in the capacity of 
pharmacists can make towards better patient care and giving educated and unbiased 
information to general practitioners. General practitioners‟ perceptions of the ability 
of community pharmacists to carry out clinically inclined roles would be hampered in 
this situation. He was also of the opinion that the academic qualifications required to 
practice as a pharmacists should be upgraded to a minimum of five-year B.Pharm 
program as in other parts of the world (Foppe et al., 2001) instead of the two-years 
diploma training presently required for registration to practice. Fortunately, South 
Africa has a well regulated pharmacy educational system as well as in the practice of 
the profession, preference for traditional roles of community pharmacists could not 
have been influenced by academic qualifications or irregular practices. More than half 
of general practitioners in the study (55.6%) disagreed with community pharmacists 
carrying out partnership prescribing (supplementary prescribing) with them. 
Partnership prescribing or supplementary prescribing is an example of inter-
professional collaboration being practiced in NHS in England, Wales, Scotland and 
Northern Ireland. Following diagnosis by a doctor or dentist, who is referred to as the 
independent prescriber, a supplementary prescriber or a dependent prescriber can 
prescribe „prescription only medicines‟ (POMs) and other classes of medicines as 
agreed with the independent prescriber for the clinical management of individual 
patients. This is different from the role extension being advocated for community 
pharmacists in South Africa (Gilbert, 1998) but it can be a starting point for 
partnership. Community pharmacists in South Africa are requesting that the scope of 
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scheduled drugs that they can prescribe independently be expanded from schedules 1 
and 2, to include specific drugs in schedules 3, 4, and 5 under defined conditions. This 
has been a source of discord between medical and pharmaceutical professions over 
the years. With the response of over half of general practitioners in the study to 
dependent or supplementary prescribing which requires collaboration between the 
general practitioner and community pharmacists, the quest for independent 
prescribing role extension would not be easily won. Gilbert (1998) suggested that 
another reasonable way of resolving the problem would be for a committee to be 
selected which would schedule some prescription drugs as non-prescription drugs so 
that community pharmacists could have access to them during consultations with 
clients. This is reasonable because it is not within the academic training of a 
pharmacist to diagnose and prescribe beyond certain acceptable limits (Feinstein, 
1985, p. 1027). However, assessment of the survey carried out on the activities of the 
community pharmacists who were given permits to prescribe with access to all the 
drug schedules in the rural areas suggested that they had more clinical and patient-
oriented practices, more interaction with other health professionals, a higher client 
patronage, attended to a wider range of cases, and were more effective members of 
the primary healthcare team. A reason for these successes might be because the 
community pharmacists were practicing in rural areas where fewer general 
practitioners might be available. Cheaper medical cost would be an attraction in any 
location if the practitioner has received the relevant training required to act in such 
capacity. In urban areas, the work load of the general practitioners would be greatly 
relieved if community pharmacists are allowed to practice in a similar capacity. A 
recent government policy has empowered pharmacists to become „authorized 
prescribers‟ in South Africa (South Africa Pharmacy Council, 2011).  
Other advanced roles of community pharmacists were acceptable to general 
practitioners in the present study at varying levels of agreement. More than half 
(51.7%) of general practitioners in this study were highly in favour of community 
pharmacists supervising repeat prescriptions for up to 6 months and participation in 
health promotion programs. The high level of agreement to these services can be 
attributed to the fact they are already being offered by community pharmacists in 
South Africa. Both services are crucial in the treatment, management and prevention 
of chronic diseases especially those associated with lifestyle. Considering the burden 
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of these diseases in South Africa where both rural and urban dwelling citizens are at 
risk (Groenewald et al., 2008), it is imperative that necessary action be taken to 
educate people on preventive measures that can be taken to reduce or eliminate the 
risk of developing these illnesses and wholesome management of those already living 
with these conditions. With enhanced collaborative practices between general 
practitioners and community pharmacists, more general practitioners and patients 
would come to appreciate the impact of these services as information on patients‟ 
adherence to therapy, and their response to therapy can be easily exchanged. General 
practitioners in America, Europe, Canada, India and many more countries support 
community pharmacists‟ involvement in health promotion programs (Bond et al., 
1995; Martin et al., 1998; Plunger et al., 2000). Bryant et al. (2009) observed that 
general practitioners in New Zealand were not in agreement with community 
pharmacists supervising repeat prescriptions for 12 months probably because it is a 
long time to keep a chronically ill patient away from medical check-up and this might 
also deprive general practitioners of financial income.  
A way of ensuring that collaboration is not limited to stage 0 is by intimating general 
practitioners of the professional competence of community pharmacists as indicated 
in models of team building like those proposed by McDonough and Doucette (2001), 
Drinka (1994), or Sullivan (1998). They outline the different stages that teams have to 
go through before reaching maturation. The CWR model proposed by McDonough 
and Doucette being used in this study outlines the first stage of collaboration to be 
stage 0 which is the professional awareness stage where interactions of a discrete 
nature occur. These are the kinds of interactions that have been observed in this study. 
For more meaningful collaborations to occur and also to improve patients‟ health 
outcomes, the other stages of the CWR model, from stage 1 need to be initiated. 
Initiation of this stage of collaboration rests with community pharmacists (Doucette et 
al., 2005). The frequency and direction of interactions are unilateral but as exchanges 
intimating the general practitioner of the services offered by the community 
pharmacists continue, and useful recommendations are made consistently over time 
(Swan & Trawick, 1987), then the general practitioner comes to trust the pharmacist‟s 
expertise. The professional competence and ability of the community pharmacist is 
recognized. Communication, trust, and dependence grow leading to more 
collaborative practices at higher stages of the CWR model. The desired collaboration 
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envisioned between general practitioners and community pharmacists in this study is 
described as the prospects of enhanced future collaboration.  
Pojskic et al. (2009) in their study observed that collaborative working relationship 
between general practitioners and community pharmacists in Ontario was low to mid 
level. They concluded that it was underdeveloped because general practitioners had 
five or fewer interactions a week with community pharmacists about patients‟ drug 
therapy management. The frequency and stage of collaboration observed here are 
much higher than what has been observed in the South African scenario.  
They also noted that very few general practitioners used pharmacists as their primary 
source of medication information. In the six months period covered in the present 
study, 51% of general practitioners have asked community pharmacists for 
information three or fewer times, only 12% of them have asked over five times. Most 
general practitioners explained that they used their official medical references often or 
they called up the Medicines Information Centre (MIC) of the pharmacology 
department in the University of Cape Town for medical information as well as other 
available sources.   
Despite general practitioners‟ good perceptions of the professional roles of 
community pharmacists and positive attitudes towards inter-professional collaboration 
with community pharmacists, why are the low-levels of current collaboration still 
being observed? Statistical evidence shows that current collaboration between general 
practitioners and community pharmacists is moderately, positively, correlated to 
general practitioners‟ perceptions of the professional roles of community pharmacists 
(p=0.008). This implies that general practitioners‟ good perceptions of the 
professional roles of community pharmacists may not yield the same level of current 
collaboration between them. Current collaboration between general practitioners and 
community pharmacists is also positively correlated with general practitioners 
attitudes toward inter-professional collaboration (p=0.007). The implication of this is 
that other factors influence inter-professional collaboration between general 
practitioners and community pharmacists besides good perceptions of the professional 
roles of community pharmacists and positive attitudes towards inter-professional 
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collaboration. Other factors such as trust, communication, dependence, role initiation, 
and role specification, are required to establish collaboration (Oandasan et al., 2006). 
Non-dispensing general practitioners were observed to have more frequent 
collaborations with community pharmacists compared with dispensing general 
practitioners (p=0.0005). The probable explanation for this is that patients who visit 
non-dispensing general practitioners always have their prescriptions filled at the 
pharmacy while patients who visit dispensing general practitioners would only visit 
the pharmacy for medications they could not obtain from the prescriber. Collaboration 
between community pharmacists and non-dispensing general practitioners is 
envisaged. 
General practitioners who had spent more than 10 years in practice had more positive 
attitudes towards inter-professional collaboration with community pharmacists 
compared to those with less than 10 years in practice (p=0.030). This may be due to 
the fact that younger general practitioners (25 to 30 years) are poorly represented in 
the study at 3.3%; this is likely because most of them undergo community service at 
this stage and have not yet found a footing in private practice. Furthermore, they are 
recent graduates, possibly filled with self confidence and having a need to prove their 
professional competence as explained earlier. Older general practitioners on the other 
hand, have over the years come to appreciate the complementary role of the 
community pharmacists and are more appreciative of collaboration. Adepu and 
Nagavi, (2006) had a similar view in a study of general practitioners carried out in 
India. 
6.2.2         INFLUENCE OF GENERAL PRACTITIONERS‟ PERCEPTIONS OF 
THE PROFESSIONAL ROLES OF COMMUNITY PHARMACISTS ON DESIRED 
COLLABORATION 
 Desired collaboration (prospects of enhanced future collaboration between general 
practitioners and community pharmacists) is positively correlated with general 
practitioners‟ perceptions of the professional roles of community pharmacists 
(p=0.0005). This means that a good perception of the professional roles of community 
pharmacists would yield the kind of collaboration desired in the future. Consequently, 
it is expected that participants in the present study have good prospects of enhanced 
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future collaboration based on the good perceptions of the professional roles of 
community pharmacists which they have exhibited. Stage 0 collaborative practices are 
favoured above other stages of collaboration. The explanation for this could be that 
these are the traditional roles that general practitioners are used to community 
pharmacists carrying out. As stated earlier, community pharmacists need to make 
general practitioners aware that they perform these other roles. Pharmacy professional 
bodies are required to organize regular training programs and courses for community 
pharmacists to keep them abreast of latest developments in medicine and pharmacy. 
Joint continuing professional education can be organized for both professionals to 
meet and exchange ideas. 
General practitioners‟ attitudes towards inter-professional collaboration is also 
positively correlated to prospects of enhanced future collaboration (p=0.0005). 
General practitioners in the present study exhibited positive attitudes towards inter-
professional collaboration with community pharmacists. A positive attitude signifies a 
positive mind-set for collaboration. Their perception of the professional roles of 
community pharmacists was also positively correlated with their attitude toward inter-
professional collaboration (p=0.0005). Good perceptions of the professional roles of 
community pharmacists and positive attitudes towards inter-professional collaboration 
should yield good prospects of enhanced future collaboration.  
 
6.2.3 WHAT ARE THE PROSPECTS OF ENHANCED FUTURE 
COLLABORATION BETWEEN GENERAL PRACTITIONERS AND 
COMMUNITY PHARMACISTS, WHAT DOES THIS ENTAIL?  
The response of general practitioners in the present study to the prospects of enhanced 
future collaboration with community pharmacists was generally positive but still 
favoured collaborative practices at stage 0 of the CWR model. All the general 
practitioners in the study consented to exchanging information on prescription issues 
that may arise during the dispensing process. This is supportive of the positive 
attitudes that they all expressed to community pharmacists contacting them if there 
were issues with their prescriptions during the dispensing process. Full consent was 
also given to exchanging information with community pharmacists in situations 
where patients had negative reactions to prescribed medication. This also 
 
 
 
 
119 
 
complements the 98.3% score on the positive attitude scale observed in their response 
to community pharmacists alerting them of possible adverse reactions in patients. 
These practices make up stage O collaboration which reflects the drug-oriented 
traditional roles of community pharmacists. General practitioners favour these roles 
because they are complementary to their own roles, and as such do not breach 
professional boundaries. There are good prospects of general practitioners and 
community pharmacists collaborating or co-managing patients especially chronically 
ill patients with only an 8.5% disagreement. This is stage 4 of the CWR model where 
formalized agreements are put in place for the joint care of patients. General 
practitioners rely on the knowledge and skill displayed by community pharmacists 
who in turn rely on the clinical information provided to manage patients‟ drug 
therapy. Exchange of patients‟ clinical information to help the community 
pharmacists make better clinical and therapeutic judgments is an essential ingredient 
in this process. Almost 80% of the general practitioners in this study agreed to 
provide such information. In the USA, postgraduate community pharmacy residency 
programs are organized by universities, pharmacy statutory bodies and community 
pharmacy organizations to develop advanced knowledge and skills in the delivery of 
pharmaceutical services in a community pharmacy setting. 
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The NHS in UK required that certain trainings should be undertaken for pharmacists 
to carry out advanced roles such as supplementary prescribing. Universities in the UK 
also organize post-graduate trainings for community pharmacists. In Australia, 
professional programmes funded under the community pharmacy agreement (CPA) 
provide trainings for community pharmacists that explored expanded roles in 
chronic disease management such as the Pharmacy Asthma Management Service 
(PAMS) which is carried out in collaboration with general practitioners. Therefore, 
community pharmacists who intend to collaborate at this stage would need to 
improve their clinical and pharmacological knowledge. Future collaboration in 
health promotion programmes such as smoking cessation, weight loss, and lipid 
management with community pharmacists was supported by 97% of general 
practitioners. Over 90% of them had shown good perception of this role of the 
community pharmacists. A response to the-open ended question (qualitative data) on 
ways of improving inter-professional collaboration commented on joint community 
health promotion programs comprising of general practitioners, community 
pharmacists, community primary health centres and other health professionals as a 
way of encouraging collaboration and also educating the community. Considering 
the burden of chronic diseases in South Africa where both rural and urban dwelling 
citizens are at risk (Groenewald et al., 2008), it is imperative that necessary action 
be taken to educate people on preventive measures that can be taken to reduce or 
eliminate the risk of developing these illnesses and holistic management of those 
already living with these conditions.   
 
Referral of patients to community pharmacists for other specialized services for which 
they are trained (for example, anticoagulation services) received the least positive 
response from general practitioners. The example used in the questionnaire could 
have influenced the response observed as most general practitioners said they were 
comfortable with the pathologists presently carrying out anticoagulation services. On 
explanation that specialized services are not restricted to anticoagulation alone, most 
general practitioners agreed that if evidenced training is undertaken, they would refer 
patients to community pharmacists. Prospects of enhanced future collaboration 
between general practitioners and community pharmacists entail communication in 
the form of information exchange between the two professionals. On the negative 
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attitude scale, the highest percentage of general practitioners did not want to give 
patients clinical information to community pharmacists. Current practice showed that 
75% of general practitioners have never given patient‟ clinical information and 20% 
of those who have done it did so 3 or fewer times in 6 months. Most general 
practitioners stated that giving out patients‟ clinical information would be a breach of 
„patient-doctor confidentiality‟. However, some of them expressed willingness to give 
information with the patients‟ consent. In a study carried out by Pojskic et al. (2009), 
general practitioners considered community pharmacists‟ lack of access to patient 
information as a disadvantage and a barrier to collaboration. This observation was 
also made in the barriers to collaboration section of this study. Fortunately, despite 
poor information exchange observed in current collaboration, future prospects of 
information exchange are quite positive.  
Trustworthiness and dependence are other necessary exchange characteristics required 
in building relationships. Other components required to ensure good prospects of 
future collaboration as indicated by general practitioners are relationship initiation 
which is most often dependent on community pharmacists, professional interactions 
are also usually pharmacists initiated and unilateral but becomes bilateral as 
professional recognition grows, competence and interdependency is established and 
role specification is understood (Zillich et al., 2004). Role specification is a major 
component of collaboration so as to prevent conflicts over trespassing of professional 
turfs as observed by Howard et al. (2003), in a study of collaboration between 
community-based expanded role pharmacists (ERPs) and family physicians in a 
seniors‟ medication assessment research trial (SMART) program carried out in 
Canada. She postulated that expected roles of general practitioners and community 
pharmacist in collaborative practices should be clarified. This is a major reason for the 
establishment of collaborative practice agreements (CPA).  
 
6.2.4 BARRIERS TO ENVISIONED COLLABORATION BETWEEN GENERAL 
PRACTITIONERS AND COMMUNITY PHARMACISTS IN PATIENT CARE 
General practitioners indicated that collaboration with community pharmacists would 
be more attractive if it is remunerated. One of the reasons for this is the extra time and 
efforts that would be required to establish collaborative partnerships with community 
pharmacists. In stage 4 collaboration of the CWR model, the point where there is 
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commitment from both parties to the collaboration, meetings are required to formalize 
arrangement for exchange of information and collaborative patient management 
(McDonough & Doucette, 2001) which are known as collaborative practice 
agreements (CPA). Howard et al. (2003), in a SMART intervention program 
concluded that compensation mechanisms for general practitioners and community 
pharmacists involved in the collaboration should be worked out. In Australia, 
government has been remunerating pharmacists involved in medication reviews in 
residential aged care facilities since 1997 and in 2001 for community patients (Rigdy, 
2010).  
Another observed barrier is the absence of a government policy or mandate 
supporting collaboration with community pharmacists. This statement suggests that if 
a mandate for collaboration is issued, the practice may be established. The issue of 
mandate and remuneration are factors that are intertwined and dependent on the 
government, and professional bodies. The human resource shortages being 
experienced in the public health sector in South Africa can be eased by recognizing 
the potentials of community pharmacists like other practitioners in primary healthcare 
and positively annexing it through collaborative practices with general practitioners 
and the expansion of the roles of the community pharmacists which is the main thrust 
for greater relevance in primary healthcare. The absence of official mandates leaves 
collaborative practices to the choice of individual practitioners resulting in a lack of 
uniformity in patient care. Several studies have reported that general practitioners saw 
the absence of government mandate or policy supporting collaboration with 
community pharmacists as a barrier (Dunlop & Shaw, 2002; Bryant et al., 2009). This 
means that individual practitioners can decide for or against collaboration. 
Governments in the United Kingdom, Canada, New Zealand, Australia and USA 
through the Departments of Health and professional bodies have policies that support 
collaboration. Sharing of patients‟ medical information with community pharmacists 
is seen as a breach of patient-doctor confidentiality as previously stated (Section 
5.4.2.3). This hurdle can be overcome by involving patients in decision making 
process considering that the patients‟ wellbeing is the reason for the collaboration. 
Farris, (2005) suggested that educating patients on the benefits of inter-professional 
collaboration to their health would result in less resistance to information sharing 
between general practitioners and community pharmacists. An example of 
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government support was the introduction of electronic transfer of prescription-related 
information between general practitioners and community pharmacies in the NHS in 
England (Porteous et al., 2003). Some general practitioners indicated that they do not 
need to collaborate with community pharmacists but the consequences and extent of 
prescription errors are well documented; increased inter-professional collaboration 
between general practitioners and community pharmacists could be believed to be 
able to reduce such consequences (Easton et al, 2009; Rigby, 2010). General 
practitioners stated that community pharmacists would favour financial gain over 
professional ethics and give biased advice to patients. Multipurpose pharmacies were 
considered to be unprofessional and distracting for healthcare practice. This view was 
also expressed in a study by Hughes and McCann, (2003). In their qualitative 
assessment of inter-professional barriers between general practitioners and 
community pharmacists, the shopkeeper image of the community pharmacist 
overshadowed his professional abilities. General practitioners suggested a “practice 
pharmacist‟s model” where community pharmacists were located within the general 
practitioners‟ practice and worked directly with them was a professional and preferred 
option.      
6.2.5 RELIABILITY OF THE INSTRUMENT 
The Cronbach‟s alpha reliability coefficient for internal consistency of scales in the 
instrument was computed to be above 0.70 which is recommended as the minimum 
acceptable value for rho (r). The scales used in the instrument for this study can be 
said to have a satisfactory internal consistency and are able to measure the intended 
constructs consistently over time. The Cronbach‟s alpha reliability coefficients for 
internal consistency of items in each scale were also calculated using the item-total 
statistics. Emphasis was focused on the “Cronbach‟s alpha if item is deleted 
measurement” as these values show the influence of individual items on the ability of 
the scale to consistently measure the construct it is intended to measure. If deleting an 
item increases the Cronbach‟s alpha reliability coefficient of the scale, that item was 
not adding value to the scale, and would not yield the same data for the construct 
being measured over time. It should be removed from the scale. If deleting an item 
from the scale causes a reduction in the Cronbach‟s alpha reliability coefficient of the 
scale, then the item would produce data that would consistently measure the intended 
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construct. For general practitioners‟ perceptions of the professional roles of 
community pharmacists‟ scale, With the exception of the item “Dispensing prescribed 
medicines to the public” which had a higher Cronbach‟s alpha if item is deleted value 
(0.83) compared to the scales Cronbach‟s alpha reliability coefficient, all other alpha 
if item is deleted coefficients were below (0.82). This can be attributed to a 
grammatical or typographical error observed during the study where the statement 
read as “dispensing prescription medicines to the public” thus creating ambiguity, 
misrepresenting the community pharmacists‟ role and the intention of including the 
statement in the scale. The item was not deleted because of the fundamental role it 
plays in the thesis. All the items in the general practitioners‟ attitudes towards 
collaboration scale had Cronbach‟s alpha if item is deleted values lower than the 
scale‟s Cronbach‟s alpha reliability coefficient of 0.77. Deleting any item from this 
scale would result in lower Cronbach‟s alpha reliability coefficient for the scale. 
Similar observations were made for items in the current collaboration between general 
practitioners and community pharmacists‟ scale, and prospects of enhanced future 
collaboration between general practitioners and community pharmacists‟ scales. All 
the items in these scales had lower Cronbach‟s alpha if item is deleted values relative 
to the scale.  
6.2.6 RESPONSE RATE 
A relatively high response rate of 70.6% was observed in this study. This could be an 
indication that general practitioners in this study are already aware of the advantages 
of inter-professional collaboration with community pharmacists, and they are 
interested in enhancing the collaboration to improve patients‟ health outcomes or 
though they are ignorant of the advantages of enhanced collaborative practices they 
are willing to learn about them. Another possible source of positive influence on the 
response rate could be the study design and data collection method which was a 
mixed method, cross sectional, face-to-face, self-administered questionnaire survey 
which gave participants an opportunity to interact with the researcher and express 
their views for qualitative data. Most participants ensured it was a once-off survey 
before consenting to participate in the survey.  The introduction of a cash incentive in 
the form of consultation fee payment also could have boosted the response rate. 
Similar studies on inter-professional collaboration between general practitioners and 
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community pharmacists carried out in Britain, Canada and New Zealand yielded 
lower response rates of 16%, 36%, and 59% respectively (Hughes et al., 2003; 
Pojskic et al., 2009; Bryant et al., 2009).  The above mentioned studies used faxes, 
postal mails and focus groups in their study. Hughes et al. (2003) also offered cash 
incentives to participants for focus group discussions involving general practitioners 
and community pharmacists and he observed a response rate of 16%. 
6.3 QUALITATIVE DATA 
The responses to the open-ended questions in the questionnaire are discussed under 
the two headings; ways of enhancing collaboration and other barriers to collaboration.   
6.3.1 WAYS OF ENHANCING COLLABORATION 
Some general practitioners in the study were supportive of inter-professional 
collaboration with community pharmacists stating that they have a good relationship 
with their local pharmacists and are already reaping the benefits of such collaboration. 
Pojskic et al. (2009) observed similar responses were obtained from general 
practitioners in Ontario, Canada to open-ended questions on interaction with 
community pharmacists. They noted that the personal attributes of pharmacists such 
as their being helpful, knowledgeable, approachable influenced collaboration. This 
observation supports the three classes of characteristics that affect the development of 
collaborative working relationships (CWR) as stated by McDonough and Doucette, 
(2001) which were also used to categorise responses obtained from study participants 
as pharmacists‟ characteristics (knowledgeable), context characteristics 
(approachable) and exchange characteristics (helpful). Pharmacists‟ characteristics 
describe the professional knowledge base and skill of community pharmacists. 
General practitioners commented that an insight of the clinical knowledge base of 
community pharmacists would make collaboration easier, while others advised that 
community pharmacists should improve their clinical knowledge as well as 
pharmacology. Professionalism was a barrier to general practitioners approaching 
community pharmacists for collaboration. The shop keeper image which has 
overshadowed the professional integrity of the pharmacists is of concern (Hughes & 
McCann, 2003). Exchange characteristics define communication which should be two 
ways, mutual respect for professional boundaries and ethics of the professions 
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(Oandasan et al, 2006). Further support for collaboration and its consequent 
advantages was expressed in the statement that “collaboration would take unnecessary 
burden off general practitioners”. This view is reinforced by the minor ailment 
scheme and repeat prescriptions undertaken by community pharmacists in England 
which saved up to 2.7 million hours of general practitioners‟ time and practice hours 
(National Prescribing Centre, 2004; DoH, UK. 2003). Both patients and general 
practitioners were found to be in support of these services (New Pharmacy Contract in 
England, 2005; Porteous & Bond, 2005). Patients who shop for dangerous drugs of 
addiction (DDAs) from different general practitioners can be monitored through 
collaborative practices with community pharmacists. 
 
6.3.2 OTHER BARRIERS TO COLLABORATION 
Barriers to inter-professional collaboration between general practitioners and 
community pharmacists not mentioned in the questionnaire used in the thesis were 
mentioned by general practitioners. These barriers were found to describe 
professional practice and health systems. Related to professional practice, some 
general practitioners were concerned that high pharmacy prices prevent indigent 
patients from visiting pharmacies eroding the need for collaboration. Others were 
uncomfortable with community pharmacists criticizing their prescriptions without 
knowing the reasons for their actions. This can be attributed in part to the inability of 
community pharmacists to access patients‟ medical records. Pojskic et al (2009), in a 
study found that general practitioners considered community pharmacists‟ lack of 
access to patient information as a disadvantage and a barrier to collaboration which 
can only be addressed through government intervention as was done in a study carried 
out by Porteous et al. (2003) to gather information on the opinions of patients, general 
practitioners and community pharmacists on the intended introduction of a system of 
electronic transfer of prescription-related information between general practitioners 
and community pharmacies in the NHS in England. The three groups were supportive 
of electronic transfer of prescription-related information. The general practitioners 
acknowledged that it improves repeat prescribing; patients expected improved 
convenience; and community pharmacists believed it would enhanced their 
professional role. Concerns were however raised about confidentiality of patient 
records (Porteous et al., 2003). The high turnover of community pharmacists in big 
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chain pharmacies and the presence of locum general practitioners and community 
pharmacists make collaboration difficult.  
Barriers related to the health system such as health policies issues and insurance 
policies were also stated. Health Professionals Council of South Africa (HPCSA) 
ethical rules and policy on dispensing were stated to be barriers to collaboration. 
Community pharmacists‟ lack of access to malpractice insurance cover was stated to 
make collaboration with them a risk. Some general practitioners stated as a barrier the 
fact that some community pharmacists dispense POMs (Prescription only medicines) 
dispensed without prescriptions. 
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CHAPTER SEVEN 
CONCLUSIONS AND RECOMMENDATIONS 
7.1  INTRODUCTION 
This chapter presents the conclusions on the findings of the study carried out in this 
thesis, how it answers the research questions set at the beginning and how it links 
with the literature that was reviewed. A list of recommendations that could help to 
enhance inter-professional collaboration between general practitioners and 
community pharmacists to improve patient health outcomes is also presented. 
Concluding remarks end the chapter. 
7.2 SUMMARY OF FINDINGS 
The results of this study indicate that using a face-to- face design method ensures 
greater participation and the introduction of consultation fees might also encourage 
participation as much as it might introduce certain biases. It is also evident that 
general practitioners have a good awareness of the professional roles of community 
pharmacists with greater acceptance of the traditional dispensing roles compared to 
the extended and advanced roles. General practitioners exhibited positive attitudes 
towards inter-professional collaboration with community pharmacists although 
currently, occurrence of inter-professional collaboration between both professions is 
low and usually at the basic level (stage 0) of interaction according to the 
collaborative working relationship model proposed by McDonough and Doucette 
(2001). General practitioners have however expressed willingness for enhanced 
inter-professional collaboration in the future. 
Absence of a government policy or mandate supporting collaborative patient 
management by community pharmacists and general practitioners, lack of 
remuneration for such services, ethical constraints on general practitioners 
preventing them from sharing patients‟ medical information with community 
pharmacists and questionable ethical practices carried out by community 
pharmacists were stated as barriers capable of hindering inter-professional 
collaboration.  
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The Literature on inter-professional collaboration has shown that with the 
government support, collaboration is achievable. A policy and the introduction of 
remuneration for general practitioners and community pharmacists in collaborative 
practice would be a great encouragement for the enhancement of collaborative 
patient management especially for the chronically ill who constitute a major health 
burden in South Africa.  
7.3  RECOMMENDATIONS FOR ENHANCING INTER-
PROFESSIONAL COLLABORATION BETWEEN GENERAL 
PRACTITIONERS AND COMMUNITY PHARMACISTS 
Some of the recommendations made here are obtained from the comments made by 
general practitioners in the course of collecting qualitative data for the research on 
ways of enhancing inter-professional collaboration with community pharmacists and 
other barriers to collaboration that were not mentioned on the questionnaire. Other 
recommendations were obtained from the reviewed literature.  
1. Community pharmacists need to make general practitioners more aware of 
their professional roles especially the extended and advanced roles. Inter-
professional training at university level should be encouraged.  
2. Community pharmacists should communicate to general practitioners how 
these roles could benefit their practice and consequently their patients. 
3. Community pharmacists should be prepared to initiate interactions with 
general practitioners for the patients‟ benefit. 
4. Community pharmacists should update their pharmacological and clinical 
knowledge regularly through a continuous professional development 
programmes. 
5. Pharmacists‟ professional bodies should make it mandatory for community 
pharmacists to obtain credits necessary for registration by attending 
continuing professional education lectures or doing on-line courses. 
6. Pharmacists‟ professional bodies should liaise with medical professional 
bodies to jointly organize continuing medical education programs as well as 
joint social events 
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7. Pharmacy professional bodies should initiate procedures to enlighten 
government and health policy making bodies of the roles of community 
pharmacists in healthcare 
8. Government policy recognizing collaborative patient management by general 
practitioners and community pharmacists. 
9. Remuneration of collaborative or co-managed patient practices. 
10. Government policy supporting a system by which community pharmacists 
can access necessary patient records. 
11. University education should emphasize an inter-professional collaboration 
amongst healthcare workers and academic interactions between medical and 
pharmacy students to help improve relationships in the future. 
6.4 CONCLUDING REMARKS 
The major concern of general practitioners and community pharmacists is the 
improved health outcome of the patient. Necessary actions that are needed to secure 
this cannot be overemphasized. To this end, identified barriers to collaboration 
should be worked on with actions that would improve inter-professional 
collaboration so as to enhance patients‟ health outcomes. This can only be achieved 
through continuous support from health practitioners, professional bodies and the 
government.   
Future research should aim at exploring the perceptions of community pharmacists 
on inter-professional collaboration in South Africa and implementing interventions 
to enhance such collaboration. 
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APPENDIX I 
 
 
 
 
FACULTY OF NATURAL SCIENCES 
Private Bag X17 Bellville 7535 
Telephone +27 21 9592190 
Fax +27 21 9593407/1276 
University of Western Cape 
13
th
 September, 2010    
 
Dear Sir or Madam, 
 
  
Introductory letter to general practitioners 
   
 
I am writing to you to discuss your possible participation in a research 
study of general practitioners in the Western Cape. Your name was 
randomly selected from a list of general practitioners registered with the 
South African Medical Association (SAMA). 
 
We are conducting a survey to find out 
 your perception of the roles of community pharmacists in health 
care  
 your present level of collaboration with community pharmacists   
and its relevance to patients therapeutic outcome 
 perceived barriers to collaboration 
 possible areas of collaboration in the future to further improve 
the quality of care received by patients. 
 
 
One of the investigators will contact you by phone towards the end of 
September (from the 20th) to discuss your participation in the study. 
You will be paid a general consultation fee for the time offered to 
participate in this survey which should be about 20 minutes. 
Participation in research is voluntary and you are not obligated to 
participate. If you choose to participate, you may withdraw at any time 
during the study.  
 
If you want to discuss this study before the investigator calls you, you 
may call Dr Kim Ward at the University of Western Cape, School of 
Pharmacy (telephone: 021-9593440  ). 
 
Thanking you in anticipation. 
 
Sincerely, 
 
 
Kim Ward (PhD)                                         Elizabeth Egieyeh (B Pharm) 
Research Supervisor.                                Student Researcher. 
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APPENDIX II 
  
 
 
 
 
FACULTY OF NATURAL SCIENCES 
Private Bag X17 Bellville 7535 
Telephone +27 21 9592190 
Fax +27 21 9593407/1276 
University of Western Cape 
` 
 
CONSENT TO PARTICIPATE IN RESEARCH 
 
 
Purpose and Background 
 
Elizabeth Egieyeh (B.pharm) and Kim Ward (Ph.D), from the 
University of Western Cape, School of Pharmacy, are conducting a 
research survey to determine the attitude of general practitioners 
(GPs) to inter-professional collaboration with community pharmacists 
(CPs). 
 
Given the extent of medication management issues and a possibility 
of more efficient use of resources within the health care system it is 
therefore important that GPs and community pharmacists cooperate to 
combine their skills in order to address and  avert such problems and 
promote judicious use of resources so as to improve patients 
therapeutic outcome. 
 
You are being asked to participate in this study because you are a 
registered medical practitioner in the Western Cape. 
 
Procedures 
 
If you agree to participate in this study, 
- You will be asked to complete a questionnaire on determining the 
attitude of general practitioners to inter-professional collaboration with 
community pharmacists.  
- The questionnaire will be returned to the investigator for analysis. 
 
Risks/discomforts 
 
1. The questions might be discomforting. 
2. You are free to discontinue your participation in the study at any time. 
3. You may discuss your discomfort with the investigator. 
4. Participation in research may involve a loss of privacy; however, your 
record will be handled as confidentially as possible. Your name will not 
be used on the questionnaire or other printed materials associated 
with the study. You name will be linked to your study number and only 
research staff will have access to this linking file. Any publications or 
presentations of the findings from this study will not include personally 
identifying information. 
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Benefits 
 
You will be providing important information on the roles community 
pharmacists play and can play in the future and how collaborating with 
them can actually help increase patient satisfaction i.e. patient 
therapeutic outcome. This may assist you in the service you provide to 
patients when they know that you and the community pharmacist they 
visit are jointly concerned about them. There may be a societal benefit 
of improved patient well-being, judicious use of resources such as 
drugs, money, time, hospital admission incidences. 
 
Costs 
 
Your time, energy, patience and experience will be required in filling 
the questionnaire. We will, however, pay your regular consultation fee 
for this time occupied. 
 
Questions 
 
Dr Kim Ward is the researcher supervising this project. You have 
talked to Mrs Elizabeth Egieyeh (0780464471) about this study. If you 
have additional questions you may call her or Dr Kim Ward at the 
University of Western Cape, School of Pharmacy (telephone: 021-
9593440) 
 
If you have any comments or concerns about participation in this 
study, you should first talk with the researchers. If for some reason 
you do not wish to do this, you may contact the University of Western 
Cape Ethics Review Board, which is concerned with the protection of 
volunteers in research projects.  
 
Consent 
 
You will be given a copy of this consent form to keep. Participation in 
research is voluntary. You are free to decline to be in this study, or to 
withdraw from it at any point without penalty of loss of benefits to 
which you are otherwise entitled.  If you agree to participate, you 
should sign below. 
 
 
______________   _______________________ 
Date     Signature of study participant 
 
      
______________        _______________________ 
Date     Signature of researcher  
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                APPENDIX III 
QUESTIONNAIRE 
 
PERSONAL INFORMATION (check as appropriate) : 
 
1. AGE :      
    
25 – 30 years  
   
31 – 40 years     
  
41-50 years 
 
51-60 years 
 
More than 60 years 
 
vi. GENDER:   
 
Male 
 
Female  
                                   
3. YEARS IN PRACTICE   : 
 
Less than 10 years         
                        
10-20 years       
                      
 More than 20 years                       
 
 4. NATURE OF PRACTICE   : 
 
Dispensing doctor      
  
Non-dispensing doctor  
 
5. LOCATION OF PRACTICE   : ……………………………      
 
6. NUMBER OF PATIENTS SEEN PER DAY : 
 
Less than 10 
 
10-20 
 
20-30 
  
More than 30 
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B.  PERCEPTIONS OF THE ROLE OF COMMUNITY   PHARMACISTS 
 
 
This section of the questionnaire seeks to ascertain your perception of the role of 
community pharmacists in the improvement of the health status of the community 
 
The roles of community pharmacists in the improvement of the health status of the 
community should include the following (tick  the box  that best represents your 
opinion): 
 
 Strongly 
Agree 
Agree  Disagree Strongly 
Disagree 
i.Dispensing prescribed 
medicines to the public  
  
 
 
 
      
ii.Carrying out X-rays and ultra-
sound scans. 
    
Iii.Providing information to 
patients on prescribed 
medicines.  
 
    
iv.Checking patients’ 
prescriptions for indications, 
safety and therapeutic 
duplications.   
 
 
        
 
 v.Reporting adverse reaction to 
drugs to prescribers and health 
authorities. 
 
        
vi.Advising on the cost-
effectiveness of medicines for 
disease states 
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 Strongly 
Agree 
Agree  Disagree Strongly 
Disagree 
vii.Monitoring patients’ 
adherence with therapy and 
ensuring their medicine related 
needs are met. 
        
viii.Monitoring blood pressure, 
blood glucose levels and 
cholesterol levels 
 
    
ix.Be a source of clinical advice 
to general practitioners, such as 
selection of a medicine for a 
particular disease state 
 
    
x.Be a source of clinical 
medicines information to general 
practitioners such as adverse 
effects of medicines 
 
    
xi.Make dose adjustments to a 
patient’s medicine using 
protocols established with 
prescribers (e.g. inhaled 
steroids in asthma) 
 
 
    
xii.Supervising repeat 
prescriptions for a patient, 
according to agreed protocols, 
for up to 6 months, contacting 
the general practitioner if a 
problem arises (continuation 
prescribing)  
    
xiii.Prescribing a medicine for a 
patient after the general 
practitioner has made the 
diagnosis, decided on the 
category of medicine required 
and given the pharmacist 
relevant clinical details 
(partnership prescribing) 
 
    
xiv.Carrying out surgical 
procedures 
    
xv.Participating in health 
promotion programmes in the 
community (diabetes screening, 
run stop smoking clinics, weight 
reduction programmes) 
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C. ATTITUTUDES TOWARD COLLABORATION WITH COMMUNITY PHARMACISTS 
 
 
This section seeks to determine your opinion on collaboration with community 
pharmacists in patient care (tick  the box  that best represents your opinion) 
 
 Strongly 
Agree 
Agree Disagree Strongly 
Disagree 
vi. Community pharmacists 
should contact me in 
cases of issues with 
my prescription 
during the dispensing 
process (e.g. dosage 
errors, contra-
indications etc.) 
   
 
   
 
ii. Community pharmacists 
should alert me of possible 
adverse drug reaction to the 
prescribed medication. 
  
 
 
 
      
iii. Community pharmacists can 
call me to refer patients to them 
for services they have specially 
trained for besides dispensing  
(e.g. anticoagulation service.) 
 
        
iv. I will accept drug  
information( dosage, drug 
interaction,…) from the 
community pharmacist  
 
        
v. I will give patients’ clinical 
information to community 
pharmacist to assist in making 
judgments 
 
    
vi. A formalized arrangement for 
exchange of information 
between the community 
pharmacists and the General 
practitioners is vital to patient 
care 
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D.  CURRENT COLLABORATION 
 
 
How many times have the following activities occurred between you and any 
community pharmacist during the past 6 months? (tick the box that best 
represents recent collaboration) 
 
 More than 
5 times 
4-5 times 2-3 times Once Never 
i. A community pharmacist 
contacted me because of 
issues with my prescription 
during the dispensing 
process (e.g. dosage errors, 
contra-indications etc.) 
 
  
 
 
       
ii. A community pharmacist 
alerted me of possible 
adverse drug reaction to the 
prescribed medication. 
 
  
 
 
       
iii. A community pharmacist 
visited/called me to request 
for patient referral for 
services beside dispensing  
for which he has specially 
trained (e.g. anticoagulation 
service) 
 
  
 
 
       
vi. I referred my patient to a 
community pharmacist for 
(iii.) above  
 
     
v. A community pharmacist 
provided me with drug 
information on asking 
(dosage, drug interaction…)  
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D.  BARRIERS TO COLLABORATION WITH COMMUN ITY PHARMACISTS 
 
The following issues may hinder my collaboration with community 
pharmacists in patients’ care (tick  the box  that best represents your opinion) 
 
 Strongly 
agree 
Agree Disagree Strongly 
Disagree 
i. The funding stream currently does 
not support pharmacists and general 
practitioners collaborating on 
medication 
management    
 
   
 
ii. Government policy now gives 
sufficient recognition to this approach 
to patient care 
    
iii. Patients may find it unacceptable 
for their medical information to be 
shared with community pharmacists 
  
 
 
 
      
iv. Other than to dispense 
prescriptions, pharmacists are on the 
periphery of the core health care team 
 
 
        
v. A community pharmacist’s 
knowledge of pharmacology and 
clinical use of medicines is 
    
 More 
than 5 
times 
4-5 times 2-3 times Once Never 
 
vi. I provided my patients’ 
clinical information to the 
community pharmacist for him 
to make better therapeutic 
judgments. 
 
     
vii. A community pharmacist 
and I have developed a 
formalized arrangement for 
exchange of information and 
provision of services. 
 
  
 
 
       
viii. How many times has such 
collaboration improved 
patients’ health outcomes? 
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inadequate to intervene on the 
patient’s behalf 
 
vi. I have sufficient confidence in my 
clinical knowledge to provide this 
service. 
 
    
vii. The patient may get conflicting 
information regarding medicines use 
        
viii.  This collaboration would not 
improve patients’ medicine-related 
health outcomes 
    
ix. I don’t feel comfortable with the 
autonomy pharmacists have when 
dealing with patients 
        
x. I don’t have the time to discuss 
patient-related medicine issues with 
community pharmacists 
    
xi. I have never been contacted by 
any community pharmacies 
    
xii. There is no community pharmacy 
practice in close proximity to my 
surgery 
    
xiii. The relationship between 
community pharmacists and general 
practitioners is too financially 
competitive to encompass this service 
 
    
xiv.Pharmacists can give biased 
advice on the use of medicines due to 
commercial pressure 
    
 
           Other barriers (please state) 
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E. FUTURE EXPECTATIONS 
 
This session seeks to know in which area you will like to collaborate with a 
community pharmacist in the future.  
 
 Prospects of enhanced future collaboration with community pharmacists 
 
As a general practitioner I would like to collaborate with a 
community pharmacist in the following areas in the future: 
 
 Strongly 
Agree 
Agree Disagree Strongly 
Disagree 
i. Collaborative care or co-
management of patients 
(especially chronically ill 
patients). 
        
ii. Exchange of patient 
information for better clinical 
and therapeutic judgments 
 
        
 iii. Referral of patients to 
community pharmacists for 
other specialized services (e.g. 
anticoagulation service) 
 
        
v.  Exchange of information 
resulting from patients’ negative 
reaction to prescribed 
medication 
 
 
    
vi. Exchange of information on 
prescription issues such as 
safety and therapeutic 
duplications 
 
 
    
 
 In what other ways do you think the collaboration between community 
pharmacists and general practitioners can be enhanced to improve the 
patients’ therapeutic outcome? 
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